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ABSTRACT 
 
Alphaviruses (genus Alphaviridae in the family Togaviridae) are positive-stranded RNA viruses 
with a nucleocapsid of eicosahedral symmetry and a lipid envelope carrying glycoprotein spikes. 
The viral genome is a single 11.5 - 11.8 kb RNA strand that has a 5’ cap structure and 3’ poly-A 
tail. The replication cycle in vertebrate cells involves entry into the host cells via receptor-mediated 
endocytosis, translation of the RNA to form the replicase proteins and successive transcription of 
RNAs with both polarities, production of structural proteins and packaging of the material into 
newly formed virions. Even though the genus includes emerging pathogens such as the Ross-River 
virus and Chikungunya virus, no vaccine or chemotherapy is currently available to prevent or 
suppress alphavirus infections in humans. 
 
Studies on alphavirus inhibitors have been scarce and mainly involved the description of broad-
spectrum antiviral agents targeting host cell enzymes. Many of these agents demonstrate a narrow 
therapeutic window or have immunosuppressive activities, which limit their clinical use as antiviral 
agents. Thus far, the only clinical study on antiviral chemotherapy for alphavirus infections was 
conducted in 2006 using chloroquine and failed to show any benefits when compared to placebo-
treated individuals.  
 
The general challenge in bioactivity screening is the need for robust, reproducible, cost-effective 
and biologically accurate assays for the screening of small organic molecules against the target of 
interest. Antiviral screening can be conducted via two basic strategies, either by phenotypic screens 
using general endpoints to measure virus replication or by screening for ligands against isolated 
target proteins validated for their relevance in virus replication. The limitation caused by the use of 
pathogenic viruses in screening can be overcome by the use of surrogate viruses or by the creation 
of replicon-containing cell lines. Replicon cell lines are generated by transfecting cells with RNA 
constructs encoding the viral replicase proteins, but lacking the genes for structural proteins. The 
constructs are typically inserted with selection markers and reporter genes and for viruses that 
induce a cytopathic effect, attenuating mutations may be required to achieve a stable cell line.  
 
In the current study, two antiviral screening assays were developed and used for the identification 
of alphavirus inhibitors. The SFV-Rluc marker virus carrying a Renilla luciferase insertion between 
nonstructural proteins (nsP) 3 and 4 was demonstrated to be genetically stable and similar to wild-
type virus in terms of infectivity in BHK21 cell culture infections. This virus allowed for the 
development of a robust luminometric assay that resulted in a Z’ value of 0.52, and approximately 
10% deviation in the normalised mid-signal. Furthermore, a replicon approach was used in the 
development of an antiviral assay against CHIKV. A BHK21-based cell line persistently expressing 
CHIKV replicase proteins with adaptive mutations in nsP2 was adopted for antiviral screening 
applying the fluorescent readout of enhanced green fluorescent protein (EGFP) marker under the 
subgenomic promoter of the replicon and activity of the Renilla luciferase produced as a fusion 
protein with nsP3. Z’ value of 0.79 and 0.74 were achieved for the fluorescent and luminescent 
readouts, respectively, and the normalised mid-signal showed approximately 5% deviation. Both 
assays were optimised for screening environment in 96-well format and validated with previously 
known alphavirus inhibitors. In addition to the new antiviral assays, methods for cell viability 
evaluation were compared and validated in automated environment to provide counter-screening 
methods to be combined with the antiviral assays.. 
 
6 
 
 
The SFV-Rluc assay was used as the primary assay for the antiviral screening of 29 nucleoside 
analogues, 51 semisynthetic betulin-derived compounds, 124 natural compounds and 234 synthetic 
drug molecules. The identified hits were counter-screened in mammalian cell viability assays. The 
confirmed hits were further characterised in secondary assays using CPE reduction, measurement 
of SFV yield and CHIKV replicon assays. 3’-amino-3’-deoxyadenosine, 3,28-O-diacetylbetulin 
and coumarin 30 were identified as the most potent SFV inhibitors with IC50 values of 16.2 µM, 9.1 
µM and 0.4 µM, respectively. The 5,7-dihydroxyflavonoids apigenin, chrysin, naringenin and 
silybin were found to suppress expression of the CHIKV replicon marker gene at micromolar 
concentrations. Among the pharmaceutical compounds, the core structure of 10H-phenothiazine 
was found in 6 of the 12 confirmed hit compounds and was considered a suitable building block for 
future antiviral studies. In conclusion, the newly developed assays were successfully used as a 
panel of antiviral and cell viability assays to identify alphavirus inhibitors with diverse chemical 
structures. 
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ABBREVIATIONS 
aa    amino acid 
ATP    adenosine triphosphate 
BSA    bovine serum albumin 
CAT    chloramphenicol acetyltransferase 
CCID50   cell culture 50% infective dose 
CHK    Chikungunya virus 
CMC    carboxymethyl cellulose 
CNS    central nervous system 
CPE    cytopathic effect 
CPV    cytopathic vacuole 
CTP    cytosine triphosphate 
DMEM   Dulbecco’s modified Eagle’s medium 
DMSO   dimethyl sulphoxide 
DNA    deoxyribonucleic acid 
EGFP   enhanced green fluorescent protein 
FBS    foetal bovine serum 
FRET   fluorescence resonance energy transfer 
GFP    green fluorescent protein 
HBSS   Hank’s balanced salt solution 
HCS    high-content screening 
HCV    hepatitis C virus 
HIV    human immunodeficiency virus 
HTS    high-throughput screening 
I     interaction index 
IC50    50% inhibitory concentration 
IFN    interferon 
IL    interleukin 
IMPDH  inositol monophosphate dehydrogenase 
kb    kilobase 
LD50    50% lethal dose 
LDH    lactate dehydrogenase 
MEM   minimum essential medium 
MOI    multiplicity of infection 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NC    natural compound 
nsP    nonstructural protein 
ONNV   O’nyong-nyong virus 
PBS    phosphate-buffered saline 
PC     pharmaceutical compound 
PFU    plaque-forming unit 
QSAR   quantitative structure-activity relationship 
RC    replication complex 
RdRp   RNA-dependent RNA polymerase 
RFU    relative fluorescent unit 
RLU    relative luminescent unit 
Rluc    Renilla luciferase 
RNA    ribonucleic acid 
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RRV    Ross-River virus 
S/B    signal-to-background ratio 
S/N    signal-to-noise ratio 
SAH    S-adenosylhomocysteine 
SAR    structure-activity relationship 
SARS CoV severe acute respiratory syndrome coronavirus 
SDS    sodium dodecyl sulphate 
SFV    Semliki Forest virus 
SINV   Sindbis virus 
siRNA   small interfering ribonucleic acid 
SPA    scintillation proximity assay 
TCA    trichloroacetic acid 
TNF    tumour necrosis factor 
TRF    time-resolved fluorescence 
VEEV    Venezuelan equine encephalitis virus 
WNV   West Nile virus 
WST-1   2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt 
wt    wild type 
Z’    screening window coefficient 
10 
 
1. INTRODUCTION 
 
Several viral diseases remain major health problem worldwides, decreasing the quality of life and 
causing deaths in both developing countries and developed Western societies (Strauss and Strauss, 
2007). The central challenge in the development of antiviral drug therapies is due to the nature of 
viruses as intracellular pathogens, which exploit host cell macromolecules and organelles to 
replicate their DNA or RNA genomes and have only a limited number of specific structures of their 
own. Although some successful antiviral agents target cellular proteins, the goal of antiviral therapy 
is typically inhibition of the processes specific and essential for virus replication to minimise the 
adverse effects on host cells. The dawn of such an approach occurred serendipitously with the 
synthesis of an acyclic guanosine analogue, acyclovir in 1973 (De Clercq, 2008). Acyclovir 
triphosphate, the active agent formed from acyclovir, is a DNA polymerase inhibitor whose 
inhibitory activity requires intracellular phosphorylation of the drug. DNA viruses, such as herpes 
simplex virus encode a deoxythymidine kinase, which has a significantly higher affinity for 
acyclovir than the host cell kinases. This feature leads to production of the active form mainly in 
infected cells, which allows for specific targeting of the antiviral effect. 
  
In 2002, a review listed a total of 20 antiviral drugs approved for clinical use (De Clercq, 2002). By 
2009, the number increased to approximately 50 licensed compounds, about half of which are 
indicated against human immunodeficiency virus (HIV) (De Clercq, 2010). Therapeutic strategies 
currently in clinical use include viral DNA and RNA polymerase inhibition, targeting of retrovirus 
reverse transcriptase by nucleosides and nonnucleoside-structured compounds, inhibition of viral 
proteases, and targeting the host cell enzymes crucial for virus replication (e.g. blockage of de novo 
guanosine synthesis by inhibiting inositol monophosphate dehydrogenase IMPDH). Besides HIV, 
antiviral drug development has mainly focused on influenza viruses and DNA viruses such as 
herpes simplex virus types I and II, while positive-stranded RNA viruses have received little 
attention in the past (Leyssen et al., 2008). However, the picture has recently changed due to the 
rise of chronic hepatitis C virus (HCV) infection as the main cause of liver failure worldwide and 
the emergence of severe acute respiratory syndrome coronavirus (SARS CoV).  
 
Single-stranded RNA viruses also include the arthropod-borne viral species (arboviruses) that 
circulate between vertebrates and invertebrate (arthropods, most commonly mosquitoes) (Weaver, 
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2005). Arboviruses are distributed in different taxonomical families (Togaviridae, Flaviviridae, 
Bunyaviridae and Rabdoviridae), and the group includes historically important pathogens such as 
the dengue virus, yellow fever virus and Japanese equine encephalitis virus. Except for the dengue 
virus, which has fully adapted for the mosquito-human-mosquito transmission cycle, most 
arboviruses spread as zoonotic infections and typically use birds and rodents as amplification and 
reservoir hosts. Recent arboviral epidemics has returned the arboviruses to general consideration 
and also revealed some unexpected features related to these viruses. The changing epidemiological 
patterns of arboviruses were probably most dramatically illustrated by spread of the West Nile 
virus (WNV) into the Western hemisphere in 1999. WNV caused several cases of fatal encephalitis 
in the New York area, and the virus has currently established itself in Northern America causing 
small epidemics in humans and domestic and wild animals (Nash et al., 2001). Since then several 
other arboviruses have been discussed as re-emerging or resurging threats due to similar changes in 
epidemiology (Gobler, 2002). From 2005 to 2007, an outbreak of the Chikungunya virus (CHIKV, 
alphavirus within the family Togaviridae) took place, estimated to affect more than 6 million 
people worldwide and involved an unexpectedly high prevalence of serious neurological disorders 
strongly, indiciatng that such concerns have not been overestimated (Pialoux et al., 2007). Notably, 
the relatively sporadic prevalence and benign clinical picture of most arboviral diseases in the past 
has contributed to the lack of vaccines and antiviral chemotherapy against many of these 
pathogens. 
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2. REVIEW OF THE LITERATURE 
2.1. Bioactivity screening  
 
Bioactivity screening refers to a spectrum of methodologies used to identify previously undescribed 
interactions between small organic molecules and biological macromolecules, most often proteins. 
The technologies currently in use for bioactivity screening have mainly been developed for the 
needs of the pharmaceutical industry as bioactivity screening currently forms the basis for lead 
discovery process (Drews, 2000). In this context, the term high-throughput screening (HTS) is 
often used to refer to bioactivity screening campaigns in which more than 10,000 assay points are 
run daily. Academic research organisations, on the other hand, typically apply more focused, 
medium-throughput screening strategies to use bioactivity screening as a tool to benefit the needs 
of basic science (Inglese et al., 2007). Chemical probes identified in bioactivity screening 
campaigns can improve our understanding of the specific biological processes that they target, help 
to dissect the relationships of related enzyme or receptor classes and give rise to structure-activity 
relationship (SAR) models. 
 
2.1.1.  Terminology and basic principles  
 
Individual screening organisations may have developed their own procedures and implementation 
paths for their HTS campaigns. The procedures and terms presented here represent a generally 
accepted strategy of bioactivity screening, which is also used in the HTS facilities of the National 
Institute of Health in the United States  (Bronson et al., 2001; NIH, 2009). 
 
The initial steps of an HTS screening campaign include HTS implementation and validation of the 
selected bioassay. Implementation of an assay in the HTS environment usually requires 
modification of the assay protocol and optimisation to minimise assay costs and provide the best 
possible reproducibility (inter-plate and inter-day variation). The optimised assay is further 
validated by conducting a pilot screen and assaying suitable standard compounds. 
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The actual screening for novel ligands of interest is initiated by conducting the primary screen with 
the validated assay, typically using a single concentration and a very limited number of replicate 
samples of each compound. Compounds scoring above the threshold values set during the HTS 
assay implementation phase are considered primary screening actives and are subjected to 
confirmatory assays. The confirmatory assay involves cherry picking of the active compounds from 
the chemical library and retesting them using the primary screening assay. The confirmed active 
compounds exhibiting dose-dependent activity are nominated as screening hits to be further 
analysed. Depending on the nature of the chemical library used, chemical validation of the hits may 
be required at some stage of the process.  The chemical identity of the hit compound is confirmed 
by reordering the sample from the vendor, obtaining the pure dry compound and/or resynthesis of 
the compound. 
 
Hit compounds typically undergo secondary assay protocols in which their activity on the target of 
interest is tested in a different assay from the primary screen to confirm the order or hit compound 
potency. Furthermore, profiling assays can be conducted in which the hit compounds are 
characterised, e.g. for their selectivity by counter-screening for affinity to related targets such as 
receptor/enzyme subclasses or assaying for related microbial species, and pathogen vs. host cell 
selectivity. 
 
2.1.2. Assay formats and detection modalities  
 
Concerning the assay design, two main categories can be distinguished: i. screening for ligands in 
assays based on isolated target molecules and ii. phenotypic assay formats to identify small organic 
molecules that shift the assay system in the direction of the desired endpoint (Bronson et al., 2001). 
The previous emphasis on screening against individual, isolated targets stems from the current view 
of a validated target molecule, most often an enzyme or receptor protein to serve as a starting point 
for lead discovery in the drug development process. A variety of assay platforms as well as focused 
chemical libraries have been published and are commercially available for the most intensely 
studied target classes such as kinases, proteases and G-protein coupled receptors.  
 
Despite the earlier focus on isolated targets, most of the recent advances in assay development have 
been seen in phenotypic assays (Johnston and Johnston, 2002). Functional cell-based assays yield 
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multiparametric readouts for the characterisation of complete signalling cascades in their native 
environments, and the introduction of high content screening (HCS) tools has rendered the 
monitoring of dynamic cellular events such as protein-protein interactions and changes in 
subcellular localisation accessible to large-scale screens (Giuliano et al., 2003). Yet phenotypic 
assays can sometimes be based on general endpoints such as cell viability (see section 2.3.); the 
most widely used approach to building phenotypic screening assays is the use of reporter gene 
systems. Reporter genes (the most commonly used of which are listed in Table 1) are markers 
whose expression level in the system is easily detectable by either the protein’s inherent properties 
(fluorescence) or by the addition of a suitable substrate (Beonstein et al., 1996; New et al., 2003). A 
variety of applications of these systems have been developed such as the use of green fluorescent 
protein (GFP) or its derivatives as a portion of a fusion protein for localisation studies (Zhang et al., 
2002). . Alternatively, by placing a reporter gene sequence in the genomic region of interest the 
changes in transcriptional activity resulting from a given signalling cascade can be readily 
monitored via a generally applicable method. Still another application of reporter genes is the 
detection of protein-protein interaction by splitting the reporter gene into two and fusing each of the 
halves with a partner in an interaction pair. The proximity of the two partners recovers the catalytic 
site of the reporter and any changes in the interaction can be read by the reporter signal (Cubitt et 
al, 1995; Giepmans et al., 2006). 
 
Generally speaking, fluorescence is the most widely used detection mode in bioactivity screening 
campaigns due to the wide variety of fluorophores and fluorescent protein variants (Eggeling et al., 
2003; Jager et al., 2003; Thomsen et al, 2007). The energy emitted as light by fluorophores can also 
be transmitted to a second fluorophore as a function of distance, which allows for the use of assay 
  
Table 1. Most commonly used reporter genes and their properties. 
Name EC Origin Detection mode 
β-galactosidase 3.2.1.23 Various bacterial species colorimetric 
Chloramphenicol 
aetyltransferase 2.3.1.28 Various bacterial species radiometric/fluorometric 
Adcquorin  Aequorea victoria luminometric 
GFP  Aequorea victoria fluorometric 
Luciferase 1.13.12.7 Photinus pyralis firefly) luminometric 
Renilla luciferase 1.13.12.5 Renilla reniformis (sea pansy) luminometric 
Alkaline 
phosphatase 3.1.3.1 Various colorimetric 
β-lactamase 3.5.2.6 Various bacterial species colorimetric 
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formats detecting the proximity of two fluorophores (fluorescence resonance energy transfer 
(FRET)). In addition to the measurement of fluorescence intensity, the readout may utilise changes 
in fluorescence lifetime and speed of fluorophore rotation (fluorescence lifetime and fluorescence 
polarisation, respectively). However, the sensitivity of fluorescent assays may be compromised by 
various experimental factors, such as fluorophore bleaching, light scattering and reagent 
autofluorescence (Gribbon et al., 2003). On the other hand, luminescence assays do not require 
excitation light but generate the emitted light from the energy released from chemical or enzymatic 
reactions. Thus, they are free from the interference caused by excitation light (Fan and Wood, 
2007; Roda et al., 2003). Luminescent assays have wide dynamic ranges and are able to linearly 
detect signals over several orders of magnitude due to the negligible background and intense light 
emission capacity. Bioluminescent luciferase enzymes are of particular use in reporter gene 
systems, and the light produced by these enzymes can also be combined with fluorescence in the 
phenomenon known as bioluminescence resonance energy transfer (BRET), which is performed in 
a similar manner to FRET (Roda et al., 2004). 
 
Classical spectrophotometric and radiometric detection modes can also be used in bioactivity 
screening, but with some limitations (Bronson et al., 2001). Intensity of the absorbed light is 
directly proportional to its pathlength (diameter of the assay liquid column), which makes the 
miniaturisation of spectrophotometric assay formats difficult due to the diminished signal window. 
The use of radioactive isotopes is limited in the screening environment by the production of large 
amounts of radioactive waste, economical reasons and the need for a filtration step to separate the 
bound radioligand from the free fraction, which may be challenging to automate and may lead to 
high signal deviation in microplate formats. The latter problem can be overcome by a specific 
scintillation proximity assay (SPA) platform where the liquid scintillate cocktail is replaced by the 
scintillating matter coated in the solid surface of assay plates or plastic or glass beads (Udenfriend 
et al., 1987). The SPA beads or the wells also contain an affinity tag for assay components and the 
light signal can be read as a response to the proximity of the radioligand and the scintillating 
matter. 
 
More recently, label-free detection systems have been developed for screening applications as this 
approach offers the opportunity to monitor the native biological process without the disturbance of 
probes (Cooper, 2006). Furthermore, label-free approaches typically allow kinetic rather than 
endpoint measurements and thus allow for more informative characterisation of the biological 
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event. Surface plasmon resonance (SPR) technologies are becoming a validated approach for 
binding studies characterising both the association and dissociation rates of binding events, and a  
variety of other assay formats using SPR are emerging (Maynard et al., 2009; Szabo et al., 1995). 
With regard to cell-based assay formats, impedance-based measurements of cell monolayers grown 
on the surface of detection electrodes have been demonstrated to be a robust and sensitive means 
for various applications involving cellular signalling and cell viability (Panke et al., 2008). 
 
2.1.3. Data quality and assay artefacts  
 
Assessment of assay performance. When large numbers of samples are run in bioactivity assays 
with a limited number of replicates the role of assay robustness and reproducibility have been 
underlined to generate reliable data. Different detection modes yield signal windows with varying 
dynamic ranges and signal and background deviations, which can sometimes make assay 
comparison and optimisation a difficult task. Assay quality parameters, such as signal-to-
background (S/B), signal-to-noise (S/N) and the assay quality coefficient Z’, are used as tools to 
control the signal window in assay optimisation and HTS implementation (Zhanf et al., 1999).   
The formulas for the three parameters are as follows: 
 
              µsignal 
S/B = _________________                   (>5) 
            µbackground  
 
             µsignal - µbackground  
S/N = ________________________ (>10)               
           √ (σsignal2 - σbackground 2) 
 
                3σsignal + 3 σbackground  
Z´ = 1 - _ _____________________  (>0.5)                
               µsignal -µbackground  
                
µsignal = signal mean  
µbackground = background mean 
σsignal = signal standard deviation 
σbackground = background standard deviation. 
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The typical threshold values for each of the parameters indicating reasonable signal robustness are 
also given in parentheses. The parameters are also used to monitor the data quality during the 
screening campaign and modifications in the formulas that take into account the number or 
replicate samples have also been introduced (NIH, 2008). After setting the assay conditions, the 
assay quality parameters are complemented by measurements of plate-to-plate and day-to-day 
variation calculated from the maximal and mid signals as well as by determination of a minimum 
significance ratio (MSR). The MSR value is calculated from the deviation in the EC/IC50 value of a 
selected standard compound in dose-response experiments carried out on separate days, and the 
value is used to define the smallest potency difference that the assay can recognise  (Brian et al., 
2006). 
 
Compound interference. Even when the assay procedure can be optimised and validated to yield 
reliable data, properties of the screening compounds may give rise to unpredictable false positive 
results in the assay implementation phase. For instance, the fluorescent nature of some organic 
small molecules is likely to cause problems in assays using fluorescent intensity as the readout. 
Many of the fluorescent probes utilise the blue end (450 – 570 nm) of the visible light spectrum 
(for example, GFP has excitation and emission maximums at 395 nm and 509 nm, respectively); 
screening libraries are rich in heterocyclic compounds that tend to absorb and emit light within 
these same wavelengths, and besides the actual screening compounds, the impurities present in 
chemical libraries are a remarkable source of interfering autofluorescence (Simeonov et al., 2008). 
Compromised assay sensitivity due to autofluorescence may force the introduction of additional 
washing steps in the assay protocol, or the problem can be avoided by the use of alternative 
detection modes such as time-resolved fluorescence (TRF). TRF probes are lanthanide chelates that 
show an extended delay between the excitation and emission phase, which allows for postponing of 
the fluorescent readout by 0.1 - 0.2 ms, which is long enough to quench the short-lived background 
autofluorescence (Gribbon et al., 2003). 
 
Screening hit lists can also be dominated by false positives generally referred to as promiscuous 
binders. These compounds typically exhibit steep dose-response relationships  and show inhibition 
that is highly sensitive to assay conditions such as ionic strecgth, pH changes or protein 
concentration. The underlying mechanism leading to promiscuous inhibition is thought to involve 
aggregate formation by the screening compounds as the formation of spherical aggregates of 30 – 
200 nm in diameter from drug-like small molecules has been demonstrated by dynamic light 
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scattering and electron microscopy. Such particles have been shown able to reversibly inhibit 
several unrelated enzymes (McGovern et al., 2002). Screening hits classified as aggregate formers 
are generally omitted from further studies and marked in databases as nonleadlike structures to 
reduce the repeated identification of false positives (Scidler et al., 2003). However, it should be 
noted that some of the clinically used therapeutics (8% in the study by Scidler et al) show 
aggregating behaviour in biochemical buffers, which makes the interpretation less obvious. 
 
Aggregates can be formed by compounds with wide structural diversity and despite some efforts no 
single chemoinformatic model is capable of reliably predicting aggregating behaviour. Aggregation 
is more likely to occur at higher micromolar compound concentrations, but a high total organic 
load may also induce aggregating behaviour at low concentrations of well-behaving inhibitors 
when compound mixtures are screened (Feng et al., 2006). In practical terms, these promiscuous 
binders can be identified by re-running the screen in the presence of a low concentration of 
nonionic detergent, which usually prevents aggregate formation and thus abolishes the inhibitory 
potency of such samples.  
 
False positives in bioactivity screens can also be caused by a more specific interaction of the 
screening compounds with probes or reporters of the assay. The most studied reporter protein in 
this respect is firefly luciferase for which competitive and noncompetitive inhibitors have been 
described with various chemical scaffolds including the widely studied natural product resveratrol 
(Auld et al., 2008a; Bakhtiarova et al., 2006, Heitman et al., 2008). Many of these compounds 
inhibit luciferase at a biologically relevant micromolar concentration and thus are often scored as 
hits in reporter gene assays using this marker. Notably, luciferase inhibitors have also been 
identified as false positives in assay platforms for reporter gene activators via the formation of 
stabilised enzyme-inhibitor complex, which diminishes reporter degradation and leads to the 
accumulation of reporter enzyme within the inhibitor-treated cells (Auld et al., 2008b).  
 
Systematic studies on luciferase inhibition by the compounds in screening collections have been 
carried out and made available as PubChem entries, show an approximate prevalence of 3% in 
diverse chemical libraries (Inglese et al., 2007). Similar reports have yet to be published on the 
specific inhibition of other reporter genes such as Renilla luciferase or GFP. Meanwhile, follow-up 
studies using a different detection system than the primary assay are the method of choice to 
eliminate false positives due to reporter protein inhibition. 
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2.2. Alphaviruses  
 
The genus Alphaviridae (in the family Togaviridae) contains 29 viruses as listed in The VIII report 
of the International Committee for the Taxonomy of Viruses (ICTV, 2005). Alphaviruses are 
animal RNA viruses infecting birds, fish, small rodents and/or larger mammals including humans 
and domestic animals (Griffin, 2001). Except for the two alphaviral species that infect marine 
organisms (Salmon pancreatic disease virus and Southern elephant seal virus), all species in the 
genus are arthropod-borne viruses (arboviruses) that circulate between their vertebrate hosts using 
Aedes, Culex and Culiseta sp. mosquitoes as vectors.  
 
2.2.1. Prevalence and recent outbreaks  
 
Whereas alphaviral species are found on all continents except Antarctica, individual viruses in the 
genus exhibit limited geographic distributions that are mainly governed by the ecology of their 
specific vector host species (Weawer, 2005). Table 2 lists the alphavirus species currently regarded 
as human pathogens together with their geographic distributions and the abbreviations used for 
each virus. Six virus species in the genus cause human diseases characterised by polyarthritis 
(Powers et al., 2007). Together with other viruses which are considered asymptomatic or 
nonpathogenic, they are referred to as Old World alphaviruses because of their classical epidemic 
sites in Eurasia, Africa and Australia. In contrast, New World alphaviruses circulate on the 
American continents. New World alphaviruses differ from their Old World counterparts in some 
aspects of their replicative process and cause diseases that primarily involve encephalitis or other 
neuronal syndromes (Calisher, 1994; Zacks and Paessler, 2010). However, Mayaro virus makes an 
exception of the rule as despite its geographic distribution in Southern America it is associated with 
an arthritogenic disease. The scope of the current study and the main focus of the following 
sections are on the Old World alphaviruses and the arthritogenic disease.   
 
The first alphaviral species were isolated during the 1940s and 1950s in Africa (e.g. the Sindbis 
virus (SINV) in 1952 in Egypt and the Chikungunya virus (CHIKV) in 1952 in Tanzania) 
(Robinson, 1955; Taylor et al., 1953). Small epidemics and individual cases of SFV, SINV, RRV 
and CHIKV have been reported from the 1960s through to the 1990s at different sites in Africa,  
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Table 2. Alphavirus species considered to be human pathogens. 
Virus Abbreviation Distribution 
Old World   
Barmah Forest virus BFV Australia 
Chikungunya virus CHIKV Africa, Asia 
O’nyong-nyong virus ONNV Africa 
Ross-River virus RRV Australia, Oceania 
Semliki Forest virus SFV Africa 
Sindbis virus SINV cosmopolitan 
   
New World   
Eastern equine encephalitis virus EEEV North, Central and South America 
Mayaro virus MAYV South America 
Western equine encephalitis virus WEEV North and South America 
Venezuelan equine encephalitis virus VEEV North, Central and South America 
 
Asia and Australia (Fontemille, 1989; Lam et al., 2001; Marhiot et al., 1990; Pialoux et al., 2007; 
Powers et al., 2007).  
 
The total number of reported alphavirus infections is relatively low compared to other arboviruses, 
such as yellow fever virus or dengue virus, but it has been suggested that the low number of 
reported cases is partly due to misdiagnosis of alphaviral infections as dengue fever (Pialoux et al., 
2007;). CHIKV and dengue virus use the same vector mosquito species for transmission, and the 
clinical picture of a mild CHIKV fever may be difficult to distinguish from dengue fever in cases 
where serology testing is not done (Carey, 1971; Nimmannitya et al., 1969). More recently, 
documented cases of dengue and chikungunya virus co-infections have been reported (Nayar  et al., 
2007; Schilling et al., 2009).  
 
In Eastern Finland, a small outbreak of Sindbis virus is seen every autumn causing from only a few 
to approximately 1,000 cases annually (Laine et al., 2004). Migratory birds are considered the main 
virus reservoir and different Culex and Culiseta sp. mosquitoes act as vectors. The disease, which is 
known as Pogosta disease (Carelian fever), is a typical mild syndrome caused by Old World 
alphaviruses and is characterised by fever, maculopapular rash or related skin lesions and rarely 
persistent joint disorders (Kurkela et al., 2005). 
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Ross-River virus (RRV) disease, the most important arboviral disease in Australia, is caused by 
infection with the corresponding alphaviral species RRV that was originally isolated near Ross 
River in Greensland, South Australia (Harley et al., 2001). RRV pools are maintained in local 
rodent species and the virus causes epizoonotic outbreaks in the wetland areas of Australia mainly 
during the season of heavy rainfall. A total of 1000 to 7000 people are affected annually by RRV 
disease. Typically, 80% to 90% of infected individuals experience incapacitating arthritic 
symptoms. 
 
After several decades of sporadic cases, alphaviruses, especially CHIKV, have emerged to the 
general knowledge as endemic viruses. In 2005, CHIKV caused a massive outbreak on the islands 
of the Indian Ocean particularly in La Réunion where 270,000 individuals (more than one third of 
the island’s population) were affected (Renardt et al., 2007). The virus rapidly spread to other 
islands in the Indian Ocean as well as India where approximately 1.7 million confirmed cases were 
reported (Kaur et al., 2008; Thavara et al., 2007). The epidemic lasted until 2007 and has been 
estimated to involve a total of more than 6 million cases worldwide (Figure 1). Imported cases in 
travellers returning from the infected areas were reported in 14 European countries, USA, Canada 
and Australia, and an outbreak of approximately 200 confirmed cases arose in Italy in 2007 
(Penning et al., 2007; Rezza et al., 2007). In 2008 and 2009, epidemic outbreaks were also reported 
from Malaysia and Singapore (Leo et al., 2009) .  The latter outbreaks raised particular concerns as 
they stand as proof that the emergence of a tropical disease, such as Chikungunya fever, may be a 
realistic risk in temperate areas and regions with modern healthcare standards and facilities. 
 
Figure 1. Endemic area of the Chikungunya virus. Information on countries among the endemic 
are are from the USA Center for Disease Control and Prevention. 
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Reasons for the re-emergence and the changes in endemic intensity of CHIKV and other 
arboviruses have been suggested to include virus genome microevolution, the spread of vectors into 
more temperate areas due to climate change and increased travelling and increasing population and 
urbanisation (Chretien and Linthicum, 2007; Gubler, 2002; Schuffenecker et al., 2006). In the 
CHIKV 2005 – 2007 outbreak, a single amino acid change A226V in the viral E1 envelope 
glycoproteins was identified in 90% of the clinical virus isolates collected after September 
2005(Schuffennacker et al., 2006; Tsetsarkin et al., 2007). This change has been linked to improved 
adaptation of the virus for replication in Aedes albopictus mosquitoes. Although this mosquito 
species was previously seen as a secondary vector for CHIKV, it has emerged as the primary vector 
in the recent outbreak especially in urban and suburban environments. 
 
2.2.2. Clinical aspects of alphavirus infections  
 
Upon vertebrate transmission via the bite of an infected mosquito, an asymptomatic period of 4 to 7 
days is usually observed before the onset of clinical symptoms (Kam et al., 2009). The first 
replicative cycles of alphaviruses in vertebrate hosts are thought to occur in dermal tissue at the site 
of the mosquito bite. Alphaviruses such as SINV and VEEV have been shown to infect 
macrophages and other antigen-presenting cells and promote their migration to the lymph nodes 
from where the virions are disseminated into the bloodstream (Gardner et al., 2000; McDonald and 
Johnston, 2000). High viremias are typical in acute alphavirus infections (109 to 1010 copies of the 
viral genome per ml of patient sera); the main viral pool being generated in the liver and spleen. 
While CHIKV and other alphaviruses have been experimentally shown to infect a variety of 
mammalian cell types, the animal models for CHIKV- and RRV-induced arthritogenic diseases 
have provided evidence that fibroblasts, epithelial cells and, to lesser extent, macrophages are the 
main cell types infected in vivo (Couderc et al., 2008; Rulli et al., 2005; Zieger et al., 2008). 
 
Most alphaviruses are strong inducers of type I interferons (IFN) and lead to a proinflammatory 
response including the induction of IL-1α, IL-6 and TNF-α (Kupper and Fuhlbrigge, 2004; Simon 
et al., 2007). The fever observed in the vast majority of infected individuals is a result of the high 
levels of proinflammatory cytokines in the bloodstream. The fever is typically high (more than 39 
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°C) and is often accompanied by maculopapular rash, other skin disorders and gastrointestinal 
symptoms such as diarrhea and vomiting (Borgherini et al., 2007; Hochedez et al, 2006; Robin et 
al., 2009).  
 
In most patients, the acute viremia is cleared from the bloodstream within 10 days  (Penning et al., 
2008). Due to the short time scale of acute infection, the adaptive immune response is not raised 
against CHIKV at this stage (Kam et al., 2009). Anti-CHIKV IgM antibodies are detectable in the 
blood of most individuals suffering from acute viremia whereas the IgG response is typically seen 
only after the viremia is cleared. Cross-reactivity of IgG antibodies is usually observed between the 
viruses of the genus, which may limit the specificity of serological tests as diagnostic tools. The 
alphaviral species are divided into seven antigenic serocomplexes based on this feature , SFV, 
CHIKV, RRV and ONNV falling into a same complex (Powers et al., 2001). 
 
Old World alphavirus infections, particularly CHIKV and RRV, are distinguished from other 
endemic arboviral diseases by the high incidence of myopathy and polyarthritis (Simon et al., 2007; 
Sissoko et al., 2009). Joint disorders are typically encountered in 10% to 30% of CHIKV-infected 
individuals and in up to 90% of RRV disease cases. These disorders usually manifest as severe and 
incapacitating arthralgia that can last up to 1 to 2 years after the acute illness. The arthritic 
symptoms resemble rheumatoid arthritis, as they are most intense in the joints of extremities, such 
as fingers, toes, wrists and ankles. The relative importance of the proinflammatory response and 
direct virus attack in the etiology of connective tissue symptoms is not clear. Alphaviral infection is 
transient, and chronic forms in these or other tissues are not known to exist. Recent studies on 
CHIKV mouse models have also demonstrated that depletion of the macrophage-derived 
proinflammatory factors significantly diminishes pathological changes in the skeletal muscle and 
joints of infected animals (Lidbury et al., 2008). However, satellite cells and fibroblast cell lines 
have been shown to be infected by CHIKV in vitro (Ozden et al., 2008; Sourisseau et al., 2007). 
Furthermore, positive immunostaining for CHIKV antigens has been seen in satellite cells and 
muscle and synovial fibroblasts in CHIKV-infected mice indicating that the symptomatic tissues 
are also the sites of virus replication (Couderc et al., 2008). Pathology induced by different 
alphaviral species may not be uniform in this respect as fever indicating the proinflammatory 
response is reported in only approximately half of Ross-River viral infections even though most of 
the patients experience long-lasting and incapacitating arthritis and myopathy (Condon and Rouse, 
1995). 
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Even though Old World alphavirus infections have been described as relatively benign, a 
significant number of neurological symptoms were observed in the most recent epidemic (Das et 
al., 2010). The CNS symptoms were especially pronounced in small children and led also to deaths 
and persistent disabilities. In La Réunion approximately 50% of infected pregnant women 
transmitted the virus to their newborns and more than half of the infected neonates developed CNS 
symptoms including seizures, encephalopathy and brain oedema (Geradin et al., 2008; Ramful et 
al., 2007; Robin et al., 2008). Permanent disabilities were detected in 10% to 20% of these cases. 
Similar CNS symptoms, autism and other behavioural disorders as well as peripheral neuropathy 
were observed in children of all ages and adults, yet as less severe forms. The ability of recent 
CHIKV isolates to infect neuronal cells is a matter of debate. Sug gestions have been made to 
support this view but the mouse models have shown either no CNS staining at all or staining of 
only cells in the choroid plexus; the latter could be linked with the brain oedema observed in many 
paediatric CHIKV patients.  
 
Attempts to develop a vaccine against CHIKV have thus far been unsuccessful due to a large 
number of adverse effects caused by the attenuated virus strains used for this purpose (Kam et al., 
2009). Medical treatment for alphavirus infection is currently limited to chemotherapy used for 
symptomatic relief as no chemical agents that suppress alphavirus replication are approved for 
clinical use. Most patients are treated with nonsalicylate anti-inflammatory drugs, analgesics and 
dermatological preparation to alleviate the skin lesions (De Lamballerie et al., 2009). 
 
2.2.3. Alphavirus genome and replication cycle  
 
Alphaviruses have a single-stranded, positive sense RNA genome that includes two open reading 
frames, a 5’ methyl cap structure and a 3’ poly-A tail (Strauss and Strauss, 1994). The 5’ two-thirds 
of the genome corresponding to the 42S RNA fraction encodes the four nonstructural proteins 
(nsP1, nsP2, nsP3 and nsP4) responsible for the activities required for intracellular amplification of 
the viral RNA. The 3’ one-third of the genome is transcribed from the subgenomic promoter to 
yield a 26S RNA encoding the viral structural proteins including capsid (C) and envelope 
glycoproteins E1 and E2 together with residual polypeptides E3 and 6k (Figure 2). Each of the viral 
proteins carries out its characteristic activities that enable different aspects of the replication cycle 
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(Kääeiäinen and Ahola, 2002). Table 4 lists the proteins encoded by the alphavirus genome and 
presents the most essential known features of each protein. 
 
Alphaviruses enter host cells via receptor-mediated endocytosis in a process requiring C-type 
lectins or in the case of in vitro infection of laboratory strains, heparin sulfate (Klimstra et al., 
2003), Once entering the endolysosomal vesicle system, the low pH in these vesicles triggers 
conformational changes in the viral envelope glycoproteins, which allows E1 protein-mediated 
fusion of the viral envelope with cellular membranes (Helenius et al., 1981; Martin et al., 2009). 
The viral nucleocapsid is thus released into the cytoplasm and rapidly dissembled via its interaction 
with the 60S ribosomal subunit to release the single copy of the RNA genome (Ulmanen et al., 
1976; Wiggler, 2009). Once the capped RNA is made available to ribosomes, the precursor 
polyprotein P1234 is translated and processed stepwise into individual nonstructural proteins. The   
 
 
Figure 2. Genomic organisation of alphaviruses. 
 
Table 3. Proteins encoded by the alphavirus genome.  
  
Protein Size (aa) Structural  elements Features 
nsP1 537 
guanosine-7-
methyltransferase 
guanylyltransferase 
RNA capping 
Membrane anchor in RCs 
nsP2 799 
5’-triphosphatase 
NTPase 
helicase 
papain-like protease 
P1234 polyprotein processing 
Regulation of  (-)-strand synthesis 
Host cell transcriptional silencing 
nsP3 482 macrodomain hyperphosphorylated region 
Targeting of RCs to endolysosomes 
Association with neurovirulence 
nsP4 614 RNA-dependent RNA polymerase Production of viral RNAs 
C 267 
basic domain 
liner regain 
trypsin-like protease 
Formation of nucleocapsid 
E1 438 glycoprotein Mediation of membrane fusion 
E2 422 glycoprotein Interaction with host cell surface 
receptors 
E3 66 secretory polypeptide Unknown function  
6k 60 residual polypeptide chain Assists in E1 folding 
The presented amino acid numbers correspond to the Semliki Forest virus sequence. 
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intermediate cleavage products and mature nsPs form the differential stages of replication 
complexes, which act to multiply the viral RNA.  
 
Early processing of P1234 results in production of the P123 intermediate and nsP4, which combine 
to use the positive RNA strand as a template for minus strand synthesis (Shuraji et al., 1994). 
Minus strand RNA is produced only at the early phase of infection and is shut down 4 to 6 h 
postinfection. Thereafter, the minus strands are used as templates for further plus strand synthesis 
under both genomic and subgenomic promoters. The virus seems to have developed delicate 
regulatory machinery to control which RNA polarity and size are preferred by using a single 
polymerase (nsP4) in each phase of the replication cycle; proteolytic processing of the P1234 
polyprotein plays a central role in this regulation. (Salonen et al., 2003; Suioanki et al., 1998; 
Vasilieva et al., 2003) Based on experimental data from various sources, a model has been built in 
which RNA synthesis is initiated by the formation of a complex of nsP4 and P123. As discussed 
above, this complex produces mainly RNAs with negative polarity. The further processing of P123 
switches the RNA synthesis to favour plus strand synthesis of mainly genomic (42S) RNA. Final 
maturation of the replication complexes by cleavage to individual nsPs guides the polymerase to 
produce subgenomic (26S) RNA, which is ultimately translated into viral structural proteins (Kim 
et al., 2004; Lemm et al., 1993; Lulla et al., 2008; Sawicki and Sawicji, 1990; Shirako et al., 1994).  
 
As with many RNA viruses, alphavirus RNA synthesis takes place in membranous organelles that 
are thought to rescue the virus from cellular defence mechanisms induced by foreign RNA 
(Salonen et al., 2005). Early in infection, replication complexes are found in plasma membrane 
invaginations that are connected to the cytoplasm by only narrow neck-like structures (Spuul et al., 
2010). In the later phase of infection, these structures are internalised asnd fused with acidic 
vesicles of the endolysosomal membrane compartment to undergo microtubule-mediated 
trafficking into perinuclear regions of the cell. Further fusion of the vesicles with one another leads 
to the formation of cytopathic vacuoles (CPVs), a generally known hallmark of alphavirus infection 
(Grimley et al., 1968). 
 
CPVs are modified organelles derived from the endolysosomal compartment that are 200 to 1000 
nm in diameter and serve as sites for plus strand RNA synthesis. The cytoplasmic side of CPVs 
carries the microstructures known as spherules. These structures are invaginations of 50 nm in 
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diameter that are identified in electron microscopy as electron-dense areas and are recognised by 
antibodies against double-stranded RNA (Frohauer et al., 1988). All four nonstructural proteins are 
present in CPVs; however, the spherules are not the sole cellular location for any of the four 
proteins (Kujala et al., 2000). Additionally, early minus strand RNA synthesis is thought to occur in 
membranous organelles, but its exact intracellular localisation has been difficult to determine due 
to the short half-life of the minus strand RNA polymerase complex. 
 
Once the capsid proteins have been translated from 26S subgenomic RNA the proteins recognise 
plus-stranded 42S RNA based on a packaging signal in nsP2 encoding region, which leads to the 
rapid assembly of 240 copies of the protein to form the icosahedral nucleocapsid enclosing a single 
copy of genomic RNA (Weigler et al., 2009). The nucleocapsid is transported to the plasma 
membrane where the envelope glycoproteins are also independently transported after proteolytic 
processing and glycosylation in the trans-Golgi network to allow for the final steps in virus particle 
maturation. A total of 240 copies of both E1 and E2 membrane glycoproteins first form 
heterodimers, which further trimerise to generate the 80 protein spike complexes integrated into the 
envelope of each virion (Mukhopahyay et al., 2006). Finally, the conformational changes involved 
in assembly trigger the exocytic events resulting in budding of the virions into the extracellular 
space. 
 
2.3. Antiviral  and cell viability screening 
2.3.1.  Assays for cell viability  
 
In biomolecular screening, the term cytotoxicity and its in vivo counterpart acute toxicity are used 
to indicate the harmful effects on basic cellular functions caused by the presence or nonspecific 
binding of a reactive chemical structure to cellular macromolecules. The phenotypic nature of cell 
viability and cytotoxicity assays refers to this range of underlying possibilities that lead to the 
decrease in cell viability. However, the predictive value of such phenotypic assays was 
demonstrated in the 1990s by studies in the MEIC (multicentre evaluation of in vitro cytotoxicity) 
framework. Despite the heterogenic nature of the experimental data used in the analyses, a linear 
correlation between in vitro cell viability IC50 values and rodent LD50 values was reported and the  
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Table 4. Assay endpoints in cell viability evaluation. 
 
Cytotoxicity and cell viability assay endpoints Example 
Cell number/amount of biomass  
quantification of total protein amount  sulphorhodamin staining 
quantification of total DNA amount  DAP staining 
Morphological integrity  
enzyme leakage assays LDH leakage assay 
dye exclusion methods propidium iodide 
Metabolic activity  
incorporation of labelled biomolecules [3H]thymidine incorporation 
reduction of fluorescent/colorimetric dyes resazurin, MTT reduction 
detection of oxygen consumption  
determination of intracellular ATP level   
 
predictive capacity was even better when comparing the in vitro IC50 values with human plasma 
LD50 concentrations (Clemedson et al., 1991). 
 
Several cell viability assay endpoints are in general use and can be categorised into three main 
classes: total cell number, morphological integrity and metabolic activity (Table 4). As such, the  
classification is only indicative and overlap does exist depending on the experimental parameters 
used. For instance, with short exposure times assay endpoints based on metabolic activity are good 
sensors of cellular stress (e.g. intracellular ATP levels rapidly decrease in response to chemical 
stress  (Mueller et al., 2004)) whereas with longer exposure times observed changes in the 
metabolic state of the culture (e.g. total ATP content) rather reflect the total amount of biomass 
(Crouch et al., 1993). 
 
Experimental artefacts have also been reported in some cell viability assays. The gold standard 
assay based on MTT tetrazolium dye [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] reduction has been shown to underestimate the toxicity of chemicals that are substrates 
and inhibitors of P-glycoprotein, the main efflux pump responsible for xenobiotic exclusion within 
cells (Vellonen et al., 2004). As MTT itself is a P-glycoprotein substrate, disturbance of the 
transport function leads to its intracellular accumulation and enhanced reduction of the coloured 
end product. Given this published example, it is likely that chemical agents affecting 
membranetransporter proteins may lead to similar problems in other assays dependent on dye 
localisation such as in dye exclusion methods used to assess plasma membrane integrity.  
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Another example of a compound-borne artefact in cell viability assays is the interference of 
antioxidants with the MTT assay. Assays using MTT and other tetrazolium salts are based on 
spectrophotometric quantification of the reduced dye produced by cellular reductases. However, the 
same reactions can occur without cells in the presence of redox cycling chemicals. Plant-derived 
antioxidants and silicon nanoparticles have been shown to lead to enhanced MTT reduction and 
thus underestimation of the harmful potential of the compounds (Bruggisser et al., 2002; Laaksonen 
et al., 2007; Peng et al., 2004). As in the case of transporter proteins, similar problems may be 
present in other dye reduction assay formats such as the widely used resazurin (AlamarBlue) 
reduction test. 
 
2.3.2. Phenotypic assays for antiviral screening  
 
The most widely used assay for phenotypic antiviral screening is the measurement of virus-induced 
cytopathic effect (CPE) (as a reference, see the list of assay methods used in reports on alphavirus 
inhibitors in Table 5). The replicative machinery of alphaviruses as well as several other viruses 
causes a severe decrease in host cell viability that leads to apoptotic cell death within 24 h of in 
vitro alphavirus infection (Frolova and Schlesinger, 1994; Levine et al., 1993). The cytopathic 
effect is visually detectable as abnormal cell morphology and detachment of cells from the culture 
plates. Early reports on the use of CPE as the antiviral endpoint involved reading of the results 
simply by visual inspection of cultures under a light microscope. Later on more quantitative forms 
of the assay have been used to increase throughput and diminish user-to-user variation. In this 
respect, most assay endpoints for cell viability described in the previous section are applicable; 
however, the same test sample-derived artefacts (effects on plasma membrane transporters and 
cellular redox state) should be considered. The most popular assay format in this respect is 
probably the use of tetrazolium salts to monitor host cell metabolic activity. The determination of 
ATP levels and dye exclusion techniques have also been used to develop HTS assays of CPE 
reduction (Li et al., 2009; Mo et al., 2008; Schmidtke et al., 2001). The emergence of label-free 
formats in cell viability assays can also provide new approaches for antiviral assays based on CPE 
as real-time monitoring of impedance in cell monolayers gives an opportunity for kinetic 
measurements of cell viability during the course of viral infection (Owens et al., 2009).  
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Other conventional assay types for virus replication can be used as secondary assays but they may 
not provide alternatives for HTS environment due to relatively low throughput capacities. A direct 
measure for viral replication is the quantification of the incorporation of labelled biomolecules, 
usually [3H]uridine, into newly produced viral RNA (Miiller et al., 1980; Smee et al., 1991). The 
replicative machinery of alphaviruses efficiently shuts down host cell transcription via the 
interaction of nsP2 with unidentified cellular factors (Frolova et al., 1999; Gorchakov et al., 2005; 
Sawicki et al., 2006), and thus the vast majority of RNA produced in infected cells is of viral 
origin. However, when nsP2 production is turned down by suppression of the infection with an 
antiviral agent, this transcriptional silencing is less intense and the balance between cellular and 
viral RNA synthesis is most likely shifted in favour of the host cell. To control this phenomenon, 
viral RNA labelling experiments require the use of actinomycin D to inhibit host cell RNA 
synthesis. However, this approach is problematic in some cases as the presence of actinomycin D is 
known to reverse the antiviral activity of ribavirin and may also give rise to similar problems with 
other compounds (Liao and Stollar, 1993; Malinoski and Stollae, 1980). 
 
Quantitative measurement of the production of new virus particles in the presence of test 
compounds can be achieved by the use of plaque titration (Dulbecco and Vogt, 1953 Sabara et al., 
2003). The method can be used in antiviral studies in a direct plaque reduction assay format or 
indirectly to quantify virus yields. In the former case, the test compounds are present in serial virus 
dilutions used to raise plaques. In the latter case, the virus is exposed to test compounds in a low-
multiplicity infection, and the collected viral yield of the infection is subjected to plaque titration.  
 
Alternatively, virus quantification can be achieved by the determination of CCID50 (cell culture 
50% infective dose) values or the haemagglutination assay. The CCID50 (alternatively called the 
tissue culture 50% infectious dose (TCID50)) has classically been used to quantify viruses for which 
plaque titration is not appropriate (LaBarre and Lowy, 2001; Reed and Muench, 1938). In this case, 
the virus is quantified based on the cytopathic effect caused by viral dilutions, and the CCID50 
value is defined as the dilution leading to a 50% decrease in cell viability.  
 
The haemagglutination reaction, on the other hand,  was originally described for the influenza virus 
and based on the ability of viral envelope glycoproteins to react with the acetylneuraminic acid on 
the surface of erythrocytes, which leads to agglutination or the visually detectable aggregation of 
cells (Donald and Isaacs, 1954). Suitability of haemagglutination assay for large sample numbers is 
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seriously limited by the need for primary erythrocytes, but the assay may still be useful in 
subtracting the properties of antiviral agents. The haemagglutination assay solely measures the 
number of viral particles in a given sample, whereas in both the plaque assay and CCID50 
determination, the infectivity of the virions also plays a central role in the results. The distinction 
between the two aspects may be of particular use when the antiviral effects relate to the maturation 
step; some maturation inhibitors cause the formation of aberrant virions with decreased infectivity, 
yet the viral titer in the first infection cycle may not be dramatically decreased. 
 
2.3.3. Use of surrogate viruses  
 
When screening for inhibitors of human pathogens, attenuated virus strains or surrogate virus 
species are typically used to reconcile safety issues and screening facility requirements (Buckwold 
et al., 2002; Julander et al., 2008; Neyts et al., 1996). Molecular details of the replication cycle of 
surrogate virus species are often known in much greater detail than the actual pathogen and suitable 
research tools such as high-quality monoclonal antibodies are more frequently available. Therefore, 
the follow-up studies of identified screening hits can be readily conducted for tracking of the 
mechanisms that underlie the antiviral activity. In this respect, Semliki Forest virus (SFV) is the 
obvious surrogate virus within the Alphavirus genus. SFV is the most widely studied virus in the 
genus with regard to the molecular details of replication, is easy to grow in cell culture systems and 
is considered safe to use. Some strains of SFV are lethal to neonatal mice yet the suitability of the 
age-dependent encephalitis model for studying the human alphavirus-borne arthritogenic disease 
has been critically discussed. Instead, the mouse models for RRV- or CHIKV-induced arthritis may 
be more relevant in this respect (Rulli et al., 2005; Zeiger et al., 2008). A single human death has 
been reportedly caused by SFV infection; in which the victim was a research scientist suffering 
from an immunodeficiency syndrome (Willems et al., 1979). 
 
In general, the amino acid sequence identity within the alphavirus genus is least as 60% for the 
nonstructural proteins and 40% for the structural proteins (Gould et al., 2009). SFV, CHIKV and 
RRV are members of the same alphavirus antigenic serocomplex indicating that they are closely 
related in terms of evolution. Viruses of the same serocomplex exhibit antibody cross-reactivity 
with each other, and the relationships are also consistent with phylogenetic analyses of E1 coding 
region sequences that show approximately 60% identity of this diverse genomic region within 
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viruses of the SFV serogroup (Powers et al., 2001). In comparison, sequence identity between the 
hepatitis C virus and its commonly used surrogate virus bovine viral diarrhoea virus (BVDV) is 
approximately 20% (Buckwold et al., 2002). 
 
The interest in alphaviruses as expression vectors for gene therapy and other applications has 
yielded some experience with the insertion of marker genes and other foreign material into 
alphavirus genomes. Constructs with duplicate subgenomic promoters have been used to deliver the 
foreign material into cells but material placed as its own transcriptional unit is easily lost during 
viral life cycles when there is a lack of selective pressure (Hahn et al., 1992; Vähä-Koskela et al., 
2003). Virus strains that are genetically more stable and less attenuated have been achieved by 
placing the markers as part of existing transcriptional units. Both structural protein coding regions 
(between the capsid and E3 sequences) and a nonstructural protein-coding region (between nsP3 
and nsP4) have been used. Additional protease cleavage sites can be utilised to allow for correct 
processing of the polyprotein precursors (Tamberg et al., 2008; Tgomas et al., 2003). Furthermore, 
constructs that are more suitable for localisation studies, and other microscopic techniques have 
been made in which the marker gene is produced as a fusion protein with nsP3  (Frolova et al., 
2006). 
 
2.3.4. Replicon cell lines  
 
The use of replicon systems as antiviral screening tools was introduced for common consideration 
by the description of cell lines carrying subgenomic RNA replicons of the hepatitis C virus (HCV) 
(Lohmann, et al., 1999; Pietschmann, et al. 2001). The replicon systems revolutionised HCV 
antiviral screening and other aspects of in vitro HCV research, which had previously relied solely 
on surrogate viruses because HCV is difficult to propagate in any available model system.  
 
In general, RNA replicons are constructs with the viral components required for amplification of 
the RNA when transfected into suitable host cells but lacking structural protein genes needed for 
the production of virus particles. The system is thus noninfectious and allows for screening against 
viruses that would otherwise require BSL-qualified facilities. The antiviral agents identified in 
replicon assays are naturally limited to target only the virus replication phase, but replicon assays 
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have been successfully used in antiviral HTS campaigns including that against the West Nile virus 
(Noueiry et al., 2007; Puig-Basagouti et al., 2006).   
 
To establish stable cell lines that persistently express alphavirus replicons, modifications in the 
virus replicative machinery are required to diminish the virus-induced cytopathic effect. 
Noncytotoxic replicons of SFV and SIN have RNA synthesis levels of 5% to 10% of the wild-type 
virus or wild-type replicons. However, the low level of RNA synthesis is not thought to be the sole 
reason for the noncytotoxic phenotype as SIN mutants with similar low levels of RNA synthesis are 
known but still have the cytotoxic phenotype (Fata et al., 2002; Frolova et al., 2002). Instead, the 
noncytotoxic phenotype of Old World alphavirus replicons relies on adaptive mutations in nsP2, 
which is the protein responsible for inhibition of host cell transcription that leads to the apoptotic 
cell death seen in alphavirus infections (Frolova et al., 1999; Frolova et al., 2002). Several 
mutations in different sites of nsP2 have been shown to result in the noncytotoxic phenotype and 
despite the distribution of these point mutations throughout distinct sites of this multidomain 
protein all the studied examples share the same features. In contrast to the wild-type counterparts, 
the mutant replicons exhibit unstable replication complexes (RC+), and as a result of constant 
recycling of replication complexes, they demonstrate the continuous synthesis of minus strand 
RNA (Sawicki et al., 2006). 
 
Differentual replication strategies between in the Old World and New World alphavirus are 
illustrated, among other things, by the replicon systems studied on these viral species. New World 
alphaviruses usually do not require mutations in the replicase proteins to gain persistent and well-
tolerated phenotypes as they recruit the capsid protein instead of nsp2 for transcriptional silencing 
of the host cell (Garmashova et al., 2007). 
 
2.4. Known alphavirus inhibitors  
 
The published reports on alphavirus inhibitors are listed in Table 5 in chronological order. The 
sections below discuss the selected examples of these compounds with the emphasis on their target 
sites and described properties. 
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Table 5. Known inhibitors of alphavirus replication. 
     
Compound Target 
virus 
IC50  
(µM) Assay method Reference 
ribavirin SFV 280* CPE reduction Huffman et al., 1973 
arildone1 SFV 8* Plaque reduction Kim et al., 1980 
chloroquine SFV 50  [
3H]uridine 
incorporation Helenius et al., 1980 
(S)-DHPA2 SFV 700* CPE reduction De Clercq et al., 1985 
neplanocin A SFV 4* CPE reduction De Clercq et al., 1985 
ribavirin-5’-
sulphamate SFV 10  CPE reduction Smee et al., 1988 
3’-fluoro-
3’deoxyadenosine SFV 14* CPE reduction 
van Aaerschen et al., 
1989 
carbodine SFV 13* CPE reduction De Clercq et al., 1990 
cyclopentyl cytosine SFV 0.8* CPE reduction De Clercq et al., 1991 
EICAR3 SFV 7* CPE reduction De Clercq et al., 1991 
VX-4974 VEEV 19  CPE reduction Markland et al., 2000 
6-azauridine SFV CHIKV 2* CPE reduction Briolant et al., 2004 
(R)-
hydroxymethyldioxa
ne 
SINV 1.0 virus yield Kim et al., 2005 
glaucogenin C SINV 0.0015 CPE reduction Li et al., 2007 
(-)-carbodine VEEV 0.8* virus yield Julander et al., 2008 
CGC320915 WEEV 9.3 Replicon 
suppression Peng et al., 2009 
*Recalculated as molar concentration based on molecular weight and the mass per volume 
concentration given in the original publication. 
14-[6-(2-chloro-4-methoxyphenoxy)hexyl]-3,5-heptane-dione. 
2 (S)-9-(2,3-dihydroxypropyl)adenine. 
35-Etinyyli-1-β-D-ribofuranosyyli-imidatsoli-4-karboksiamidi. 
4N-[3-[3-[3-Methoxy-4-(5-oxazolyl)phenyl]ureido]benzyl]carbamic acid tetrahydrofuran-3(S)-yl 
ester, merimepodib. 
5{[4-(4-fluorobenzyl)-4H-thieno[3,2-b]pyrrol-5-yl]carbonyl}-N-(2-furylmethyl)piperidine-4-
carboxamide. 
 
 
2.4.1. In vitro studies on alphavirus inhibitors  
 
Among the earliest reports on alphavirus inhibition by small organic molecules were studies on 
ribavirin, a guanosine analogue with a broad antiviral spectrum and an IC50 value of 70 µg/ml 
(approximately 280 µM) against SFV (De Clercq et al., 1985; Huffman et al., 1973; Sarver and 
35 
 
 
 
Srollar, 1978).  Ribavirin has also been reported to act synergistically with the C-nucleoside 
analogues tiazofurin and selenazofurin against Venezuelan equine encephalitis virus (VEEV) 
(Huggins et al., 1984) and with interferon α against CHIKV and SFV (Briolant et al., 2004). The 
latter has been considered particularly useful due to the sensitivity of alphaviruses to interferon, but 
no in vivo studies have been published on this combination thus far. 
 
Since the early reports the mechanistic studies on ribavirin have covered at least four alternatives: 
inhibition of a cellular inositol monophosphate dehydrogenase (IMPDH) enzyme; inhibition of 
viral polymerases by ribavirin triphosphate; inhibition of the guanylyltransferase activity required 
for virus RNA capping and induction of error catastrophe by incorporation of ribavirin triphosphate 
into newly synthesised RNAs (Cassidy et al., 1989; Craci et al., 2002; Goswami et al., 1979; 
Toltzis et al., 1988). The relative importance of the alternatives in alphavirus inhibition has not 
been examined, but studies on flaviviruses indicate that the antiviral IC50 values of ribavirin in 
different cell culture systems are well correlated with the GTP depletion IC50 values . (Leyssen et 
al., 2005). Thus, a generally accepted view regards IMPDH inhibition is the major target that yields 
the antiviral activity of ribavirin at least in vitro. IMPDH is a cellular enzyme catalysing a rate-
limiting step in de novo guanosine biosynthesis. Inhibition of enzymatic activity leads to a decrease 
in the cellular GTP pools in situations where GTP is consumed in large amounts, such as during the 
extensive synthesis of viral RNA (Colby et al., 1999). 
 
While IMPDH inhibition seems to be the main mechanism of action against flaviviruses, overlap 
between the mechanisms has also been suggested. Decreased GTP levels may promote the 
incorporation of ribavirin triphosphate into viral RNA and thus expose the virus to the error 
catastrophe. (Day et al., 2005) In the case of alphaviruses, the mechanistic data on ribavirin are 
limited to the characterisation of SINV mutants that carry point mutations in the nsP1 coding 
region and are resistant to ribavirin (Scheidel et al., 1987; Scheidel and Stoilar, 1991). Such 
mutations have been postulated to lead to an enhanced affinity of the nsP1 protein for guanosine, 
which would rescue the RNA capping activity of the protein at low GTP concentrations.  
 
In contrast to ribavirin, mycophenolic acid is nonnucleoside structured, irreversible inhibitor of 
IMPDH clinically approved as an immunosuppressing agent to prevent host rejection complications 
36 
 
in organ transplants including liver transfers in patients with chronic hepatitis C virus infection  
(Kitchin et al., 1997). Mycophenolic acid is a potent inhibitor of various viruses in  
vitro, and IMPDH is generally considered the underlying factor for the antiviral activity (Diamond 
et al., 2002). However, the activity of mycophenolic acid in the HCV replicon has been suggested 
to be guanosine-independent (Henry et al., 2006). As mycophenolic acid does not have nucleoside 
structure and is thus not likely to incorporate into viral RNA, induction of the error catastrophe 
does not seem plausible in this case. With regard to alphaviruses, the antiviral efficacy of 
mycophenolic acid has been shown against SFV and SIN; mutant SINV strains resistant to ribavirin 
also show cross-resistance to mycophenolic acid (Scheidel et al., 1987).  
 
Also a structurally unrelated IMPDH inhibitor VX-497 has been  demonstrated to inhibit VEEV 
with an IC50 value of 19 µM (Markland et al., 2000). This broad-spectrum antiviral agent is under 
clinical evaluation for the treatment of chronic HCV infections under the generic name 
merimepodib; it resembles ribavirin in the sense that it does not bind covalently to IMPDH. 
However, VX-497’s high affinity for the enzyme makes it practically noncompetent in nature 
(Marcelin et al., 2007; Rustgi et al., 2009). Chemical structures of the three IMPDH inhibitors 
ribavirin, mycophenolic acid and VX-497 are presented in Figure 3. 
 
 
Figure 3. Chemical structures of the IMPDG inhibitors ribavirin (A), mycophenolic acid (B) and 
VX-497 (C). 
 
Another cellular enzyme described as a target for alphavirus inhibitors is S-adenosylhomocysteine 
(SAH) hydrolase. SAH hydrolase is responsible for the breakdown of S-adenosylhomocysteine, 
which is formed as the end product in methyltransferase enzyme reactions using S-
adenosylmethionine as a methyl donor (Kloor and Osswald, 2004). Inhibition of SAH hydrolase 
leads to accumulation of SAH in the cytoplasm and the subsequent suppression of 
methyltransferase activity. In the context of alphaviruses, the accumulation of SAH suppresses the 
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methyltransferase activity of nsP1 involved in the capping of viral RNA. The usability of this 
approach has been demonstrated by the potent inhibition of SFV by the SAH hydrolase inhibitors 
neplanocin A and, with weaker potency for (S)-DHPA (Table 5) (De Clercq et al., 1985). However, 
since the publication of these two antiviral agents, no other published reports have emerged on this 
aspect of alphavirus inhibition. 
   
Cellular enzymes also suggested as targets for alphavirus maturation inhibitors include 
membranous furin and other related preprotein convertases that were studied for their ability to 
cleave the E3-E2 intermediate polypeptide into mature structural proteins in the African CHIKV 
strain (Ozden et al., 2008). Decanoyl-RVKR-chloromethyl ketone (dec-RVKR-cmk), an inhibitor 
of furin, was found to abolish cleavage of the E3-E2 intermediate polypeptide into the 
corresponding structural proteins and thus leads to the production of aberrant virions with 
significantly decreased infectivity. Treatment of myoblast cells with 100 µM dec-RVKR-cmk 
resulted in a decrease in CHIKV titer by two orders of magnitude. However, the main drawback of 
this strategy is that the E3E2 cleavage site is not conserved in different CHIKV strains. The authors 
also observed that a different spectrum of preprotein convertases prefer the cleavage site in Asian 
CHIKV strains; therefore, the development of a specific and well-tolerated furin inhibitor to be 
used as an anti-CHIKV agent might be a difficult task. 
 
In 2005, synthetic dioxine derivatives were reported to inhibit SIN by the proposed mechanism of 
targeting the hydrophobic pocket in the SINV capsid protein and thus preventing virus 
nucleocapsid assembly and blocking the interaction site of the E2 glycoprotein with the capsid 
protein (Kim et al., 2005). The active structure was originally found by accident due to 
cocrystallisation of solvent dioxine molecules during attempts to determine the X-ray structure of 
SIN capsid protein. However, the study represents the first and thus far the only published work 
using structure-based drug design for the identification of alphavirus inhibitors as the authors used 
molecular docking to design and optimise the linker moiety connecting the two dioxine rings and 
allow for similar positioning as seen with the cocrystallised solvent molecules. The derivatives 
were assayed for the reduction of SINV yield; in which (R)-hydroxymethyldioxane showed 50% 
inhibition at a concentration of 1 µM. 
 
Miller and coworkers reported an HTS campaign on New World alphaviruses using a Western 
equine encephalitis virus (WEEV) replicon cell line in the primary assay (Peng et al., 2009). 
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CGC32091, a thieno[3,2,b]bipyrrole derivative, was discovered as the lead compound in the screen 
and the results from structure-activity relationship studies with compounds sharing the same 
backbone revealed submicromolar IC50 values for six of the twenty derivatives studied. The target 
site of action of CGC32091 and its analogues was not determined against WEEV, but the authors 
pointed out that the same compound has been recently shown to inhibit the hepatitis C virus RNA-
dependent RNA polymerase (RdRp) (Ontoria et al., 2006). In the case of WEEV, the compound 
was originally found as a hit in a replicon assay indicating that its target site against WEEV lies in 
the replication phase rather than in virus entry or maturation, which makes RdRp a plausible target 
candidate for also the WEEV inhibition. 
 
2.4.2. Alphavirus inhibitors with described in vivo properties  
 
The carbocyclic cytosine analogue carbodine (cyclopentenyl cytosine) was described in 1990 as a 
broad-spectrum antiviral agent that inhibits several unrelated virus species including DNA viruses 
and positive and negative stranded RNA viruses (De Clercq et al., 1990). The molecular target of 
carbodine was identified as the cellular enzyme cytidine triphosphate (CTP) synthetase, which is 
responsible for the maintenance of cellular CTP pools by the conversion of uracil triphosphate 
(UTP) to cytidine triphosphate (CTP). It was later found to be the D-enantiomer of carbodine, (-)-
carbodine that exerts the antiviral activity and suppresses CTP production (Julander et al., 2008). (-
)-Carbodine exhibited an IC50 value of 0.2 µg/ml against VEEV in a virus yield assay. It was 
demonstrated to reduce VEEV titers in infected mice brain tissue as well as relieve the symptoms 
and prolong the mean survival days of infected mice. Notably, in vivo antiviral activity was 
observed when (-)-carbodine was administered as late as 4 days postinfection when the VEEV 
vaccine strain TC-83 was used. However, the dosage required to achieve the antiviral effect was 
high (200 mg/kg) and achieving similar levels in humans may be difficult due to severe adverse 
effects. 
 
A recent report on alphavirus inhibitors introduced a novel mechanism of action by seco-pregnane 
steroids isolated from two plants used in traditional Chinese medicine (Strobilanthes cusia and 
Cynanchum paniculatum; Li et al., 2007). Glaucogenin C and its glycosides cynatratoside A and 
paniculatumosides C, D and E were shown to specifically inhibit the production of subgenomic 
RNA of viruses from the alphavirus-like super family. The authors also reported the protective 
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effect of one of the compounds in a mouse model of SINV infection. However, the protective effect 
required the administration of the compound prior to or at the same time as viral inoculation; 
administration of the compound 4 h postinfection failed to rescue the mice. 
 
Chloroquine is thus far the only chemical agent used in a placebo-controlled clinical trial for 
treating alphavirus viremias. The antiviral effect of chloroquine against alphaviruses was 
discovered in the early 1980s as the accumulation of chloroquine and other lipophilic amines into 
lysosomes was demonstrated to inhibit the SFV uncoating process (Helenius et al., 1982). As a 
consequence of base accumulation the increased lysosomal pH disturbs the membrane fusion of the 
viral and lysosomal membranes required for successful release of the viral genome into the 
cytoplasm. The same phenomenon is seen also with other weak lysosomotropic bases including the 
well-studied anti-influenza agent amantadine, which inhibits SFV although it is significantly 
weaker (IC50 value of 500 µM). Chloroquine has been introduced as an antiviral agent in clinical 
trials against HIV because a similar entry route is exploited by most enveloped viruses, and its 
antiviral activities are currently known to also involve interference with the pH-dependent steps in 
virus maturation (Savarino et al., 2003). 
 
However, the double blind clinical trial in La Réunion with 54 patients suffering from acute 
CHIKV viremia during the recent outbreak failed to demonstrate any significant difference 
between chloroquine and placebo-treated groups in the duration of the febrile illness or decrease 
the viral titers measured from blood samples (De Lamballerie et al., 2008). Chloroquine has 
previously shown indications of worsening the condition of SFV-infected mice in an encephalitis-
based animal model; and despite its potent in vitro alphavirus inhibition, the use of chloroquine in 
antialphaviral therapy is discouraged (Maheshwari et al., 1991; Savarino et al., 2007). 
 
The raised profile of alphaviruses in recent years has also led to the development of 
biotechnological products against alphaviruses. Phosphorodiamidate morpholino oligomers (PMO) 
are antisense oligomers with modified backbones, which have been designed against the 5’ 
noncoding region of VEEV and exhibit potent inhibition of the virus production of multiple VEEV 
strains in cell culture systems (Paessler et al., 2009). PMO oligomers can be readily administered 
intranasally to animals, and the antisense agent was shown to yield 100% survival of mice infected 
with a pathogenic VEEV strain when treated with PMOs before and after infection. When only 
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postinfection treatment was used, the agent yielded 64% protection. The treatment was well 
tolerated and resulted in reduced viral titers in the CNS and peripheral tissues of all animals. 
 
To summarise, studies on alphavirus inhibitors have been scarce in the past decades and involved 
only broad-spectrum antiviral agents that have been reported as inhibitors of alphaviruses as a part 
of a panel of unrelated viral species. However, the first specific agents have more recently 
appeared. Additionally, advances have been seen in the field of biotechnological products. 
Unfortunately, these products are beyond the reach of public health services in most alphavirus 
epidemic areas and are not likely to change the management of alphaviral diseases in near future. 
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3. AIMS OF THE STUDY 
 
Antiviral screening relies on robust and reproducible assay methods that allow for rapid evaluation 
of a large number of samples in a biologically relevant setup. To meet these needs in alphavirus 
antiviral lead discovery, the aims of the current study were to develop and validate antiviral assays 
using relevant alphaviral species and to establish reliable counter-screening methods for cell 
viability evaluation. 
 
To achieve the overall aims, the following approaches were used: 
 
- to validate and compare three cell viability assay methods based on LDH leakage, 
WST-1 reduction and ATP level determination (I);  
- to use a marker gene containing a strain of the Semliki Forest virus to develop an 
antiviral assay covering the complete virus replication cycle as a target for antiviral 
activity (II); 
- to develop a screening system for Chikungunya virus using a cell line stably 
expressing the CHIKV replicon with marker genes inserted (IV);  
- to validate and compare the antiviral assays using reference assay methods and 
standard compounds (II and IV); 
- to demonstrate the performance of the assays in the identification of antiviral agents 
among small organic molecule collections with diverse chemical structures (II, III 
and IV). 
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4. MATERIALS AND METHODS 
 
The following section provides an overview of the methods used in the study. Detailed 
experimental protocols are presented in the Materials and Methods sections of each original 
publication I-IV. 
 
4.1. Compound libraries  
 
Four small organic molecule libraries were included in the study and contained natural products, 
semisynthetic derivatives of natural compounds and synthetic drug molecules. Twenty-nine 
biocatalytically produced nucleoside analogues were provided by Professor Seppo Lapinjoki 
(Department of Pharmaceutical Chemistry, University of Kuopio, Finland), and a set of 51 
synthetic triterpenoids derived from betulin and betulinic acid were synthesised at the Division of 
Pharmaceutical Chemistry, University of Helsinki by the research group of Professor Jari Yli-
Kauhaluoma. The in-house natural compound library (n = 124) consisted of commercially available 
pure plant secondary metabolites, which were mainly flavonoids, coumarins and other polyphenols. 
The collection of pharmaceutical compounds (n = 234) contains clinically approved drugs in 
different therapeutic areas as well as some metabolites of the drugs. All compounds in the natural 
and pharmaceutical compound collections were purchased from various commercial sources (see 
supplementary table in IV for complete listing). All libraries were maintained as DMSO stock 
solutions at 20 mM concentrations except for the betulin-derived compounds for which 10 mM 
stock solutions were prepared. The chemical libraries were stored at – 20 °C, and each aliquot was 
subjected to a maximum of 10 freeze-thaw cycles. 
 
4.2. Standard compounds 
 
In I, known cytotoxic agents were used to validate the assays. Gramicidin S, polymyxin B, 5-
fluorouracil, camptothecin and Triton X-100 were all purchased from Sigma-Aldrich. Polymyxin B 
(10 000 IU/ml) was also used as a positive control in all further cell viability studies. Antiviral 
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standard compounds of ribavirin (II, III and IV), mycophenolic acid, 6-azauridine and chloroquine 
(IV) were purchased from Sigma-Aldrich. 
  
4.3. Cells and viruses 
 
Baby hamster kidney BHK21 cells were purchased from the American Type Culture Collection 
(ATCC) and used for all antiviral assays. In the cell viability assays, three human cell lines were 
used together with BHK21 cells. Human colon carcinoma Caco-2 cells were a kind gift from 
Professor Arto Urtti (Centre for Drug Research, University of Helsinki), and the Calu-3 cell line 
was purchased from ATCC. Hepatocellular Huh-7 cells were a gift of Dr. Ralf Bartenschlager 
(University of Heidelberg, Germany) and used in I, II and III. The BHK-CHIKV-NCT cell line 
persistently transfected with the CHIKV RNA replicon was selected in the laboratory of Dr. Andres 
Merits, University of Tarto, Estonia as described in IV. The fluorescence excitation and emission 
maximum of the cell line were defined as 478 nm and 509 nm, respectively, using the Varioskan 
Flash multimode platereader (Thermo Fischer Scientific Inc.). 
 
All virus stocks were propagated by the electroporation of BHK21 cells with RNA obtained by in 
vitro transcription of cDNA plasmids containing the full-length infectious clones of each virus. 
Wild-type Semliki Forest virus was obtained from plasmid SFV4 and Sindbis virus from plasmid 
TOTO1101 (Liljeström et al., 1991; Rice et al., 1987). The cDNA plasmid for SFV-Rluc-H2, a full-
length infectious Semliki Forest virus inserted with the Renilla luciferase coding sequence, was a 
kind gift from Dr. Andres Merits (University of Tarto, Estonia). The luciferase marker was placed 
in the SFV-Rluc genome in a similar manner as EGFP in Tamberg et al., 2007. 
 
4.4. Antiviral assays 
4.4.1.  [3H]uridine incorporation assay (II) 
 
Viral RNA synthesis rates were determined by the quantification of [3H]uridine incorporation in 
infected BHK21 cell cultures. Briefly, confluent cell cultures in 6-well plates were infected with 
wild-type virus (SFV or SINV), and a 1-h pulse of 15 µCi of [3H]uridine (Amersham) was given to 
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the cultures at selected time points. Prior to the uridine pulse, cells were treated for 1 h with 5 
µg/ml actinomycin D to inhibit host cell RNA synthesis. After the uridine pulse, cultures were 
washed three times with PBS and lysed with 1% sodium dodecyl sulphate (SDS). The lysate 
samples were precipitated with 10% trichloroacetic acid (TCA), and the precipitates were collected 
on glass fibre filters for scintillation counting (MicroBeta Trilux, PerkinElmer Life and Analytical 
sciences Inc.). 
 
4.4.2. Virus-based reporter gene assay (II, III and IV)  
 
A luciferase-based screening assay was developed by exploiting the SFV strain containing the 
Renilla luciferase gene inserted in its nonstructural protein-coding region. In this assay, confluent 
BHK21 cell cultures in 96-well plates were infected with SFV-Rluc, and the Renilla luciferase 
activity of the samples was determined at selected time points using the Renilla Luciferase assay 
system kit (Promega). The infection medium was removed, wells were washed with PBS and cell 
culture lysis reagent was added to the wells. After a 15-min incubation at RT, luciferase substrate 
solution was added, and the luminometric readout was taken within 5 min in the Varioskan Flash 
(Thermo Fischer Scientific Inc.).   
 
4.4.3. Plaque assay (II and IV) 
 
In the plaque assay, confluent BHK21 cell cultures in 6-well plates were inoculated with 10-fold 
serial dilutions of SFV, and the infected cultures were incubated in carboxymethyl cellulose (CMC) 
medium for 48 h. The cultures were then washed and stained with crystal violet to visualise the 
plaques. The plaque titration method was used to quantify viral yields either as in the plaque 
reduction format (II) or the virus yield assay (IV). In the plaque reduction assay, test compounds 
were simultaneously administered to the cultures with the virus inocula and remained there 
throughout the 48-h incubation. In the virus yield assay, BHK21 cell cultures were infected with 
SFV (multiplicity of infection (MOI) = 0.01) in MEM + 0.2% BSA and the medium was harvested 
16 h postinfection. Virus in the harvested samples was quantified by plaque titration. 
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4.4.4. CPE reduction assay (IV) 
 
CPE reduction was assayed using confluent BHK21 cell cultures in 96-well plates infected with 
either wild-type SFV or SINV (MOI = 0.01). After optimised infection times (22 h for SFV and 24 
h for SINV), the cultures were washed, and host cell viability was determined using the WST-1 
reduction method (see Section 4.5.2.). 
 
4.4.5. Guanosine supplementation studies (III and IV) 
 
Antiviral agents ribavirin (III and IV) and mycophenolic acid (IV) were characterised in the SFV-
Rluc screening assay and in the BHK-CHIKV-NCT replicon cell line by guanosine 
supplementation experiments during which 50 µg/ml guanosine (Sigma-Aldrich) was administered 
simultaneously to the cell cultures with each antiviral compound. The detection in both assays was 
carried out as described in Section 4.4.2. 
 
4.4.6. Administration time experiments (III) 
 
Three betulin-derived compounds and 3’-amino-3’deoxyadenosine were subjected to 
administration time experiments using an MOI of 10 for the infection of SFV-Rluc. After 1 h of 
virus adsorption, the virus inoculum was removed, and the cultures were washed twice. Luciferase 
activity was determined 5 h postinfection. Compounds (200 µM) were present in the infected 
cultures either throughout the infection (0 – 5 h), during viral adsorption (0 – 1 h) or after delayed 
administration (1 – 5 h or 2 – 5 h). 
 
4.4.7. Synergism studies (III) 
 
To study the potential synergistic inhibition by betulin-derived compounds with 3’-amino-3’-
deoxyadenosine, the IC50 values of three selected betulin derivatives were determined alone and in 
the presence of 0.5 µM, 2 µM, 5 µM, 20 µM and 50 µM nucleoside. The IC50 values were used to 
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generate isobolograms as described in Gerco et al., 1995. Here, the NE-SW diagonal of the graph 
crossing the axes at (0, 1) and (1, 0) represents the Loewe additivity or expected response for the 
given combination. Bending of the graph below the additivity diagonal is a hallmark of Loewe 
synergism. To analyse intensity of the synergism in individual concentration combinations, 
interaction indices (I) were calculated for each normalised surviving fraction that resulted from a 
given combination using the equation I = D1/DX1 + D2/DX2, where D1 and D2 represent the 
concentrations of compounds 1 and 2 in the combination and DX1 and DX2 represent the 
concentrations of drug 1 and 2 alone that yield the same response.  
 
4.5. Cell viability assays 
4.5.1. LDH leakage assay (I) 
 
LDH activity in samples of medium collected from cell cultures exposed to test compounds was 
determined by the method described by Korzeniewski et al. (1983). Briefly, the medium samples 
were mixed with an equal volume of substrate solution containing lactic acid, iodonitrotetrazolium 
chloride  (INT), nicotinamide adenine dinucleotide (NAD+) and phenazine methosulphate. After 30 
min of shaking, the enzymatic reaction was stopped by adding 1 M acetic acid, and the absorbance 
resulting from the reduction of INT by NADH was read at 490 nm (Victor Multimode platereader, 
PerkinElmer Life and Analytical Sciences Inc.), At 24 h of exposure, the assay was utilised to 
determine total cell content in cultures exposed to test samples. Here, wells were washed with 
Hank’s balanced salt solution (HBSS) and lysed with 9% Triton X-100. The LDH activity of each 
lysate was assayed as described above. 
 
4.5.2. WST-1 reduction assay (I, II and IV) 
 
WST-1 (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium 
salt) is a tetrazolium salt that produces a water-soluble formazan product as a result of its reduction 
by cellular enzymes (Ishiyama et al., 1993). After exposure to assay samples, cells were washed 
and incubated in HBSS containing 10 µl of the WST-1 solution (Roche Diagnostics) for 2 hours. 
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Intensity of the absorbance by the formazan product was read at 440 nm (Varioskan Flash, Thermo 
Fischer Scientific Inc.). 
 
4.5.3. ATP level determination (I, II, III and IV) 
 
Intracellular ATP levels were determined using the ATP-dependent firefly luciferase reaction 
(Crouch et al., 1993). The CellTiter-Glo luminometric cell viability assay kit (Promega) was used 
for this purpose. The one-step assay procedure involves treatment of cell cultures with the assay 
reagent, which contains lysis buffer and components for the enzymatic reaction and subsequent 
luminometric readout (Varioskan Flash, Thermo Fischer Scientific Inc.). 
 
4.6. Data analysis 
 
All cell viability and antiviral screening data were normalised using untreated and uninfected 
control samples to set minimum and maximum values. The assay quality parameters S/B, S/N and 
Z’  (see section 2.1.3. for formulas) were used for assay optimisation. Inter-plate and inter-day 
variations for each assay were determined as the deviation of the normalised mid-signal that was 
calculated from cultures treated with the appropriate concentrations of ribavirin (antiviral assays) or 
polymyxin B (cell viability assays). Relative IC50 values for the antiviral and cytotoxic effects were 
determined by fitting data from dose-response experiments into sigmoidal dose-response curves 
using nonlinear regression analysis in GraphPad Prism software versions 3.0 and 5.0. Selectivity 
indices were calculated as the ratio of cell viability and antiviral IC50 values. One-way ANOVA 
and unpaired t-test were used to evaluate the statistical significance of differences in IC50 values. 
For synergism studies (III), the Loewe additivity model was used to evaluate the expected antiviral 
activities of combinations of betulin-derived compounds and 3’-amino-3’-deoxyadenosine. 
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5. RESULTS 
 
5.1. Validation and comparison of cell viability assays [I]  
 
As selectivity for the target virus is one of the essential features of any antiviral drug, cell viability 
assays are required as counter-screens in all antiviral screening efforts. Various endpoints are used 
for cell viability and cytotoxicity assays, which have led to sometimes confusing interpretations of 
the results. In the first part of this study, three cell viability assays were automated and validated, 
then compared using the standard compounds gramicidin S, polymyxin B, 5-fluorouracil, 
camptothecin and Triton x-100.  
 
The assays were established using the Caco-2 cell line to select suitable cell density and buffer 
conditions. The protocols were taken to the Biomek FX workstation for automated liquid handling, 
Where the procedures were further optimised for reproducibility by using the assay quality 
parameters S/B, S/N and Z’. Parameter values for the assays are presented in Table 6, indicating the 
optimal assay performance.  
 
Table 6. Assay quality parameters of the three cell viability assays.  
Assay 
 
S/B S/N Z’ 
Inter-
plate 
variation 
Inter-day 
variation 
LDH leakage 7.9 63.9 0.72 8.9 2.4 
WST-1 reduction 36.5 104.8 0.54 11.4 18.4 
Determination of ATP level  388.6 18.1 0.83 7.1 2.7 
The formulas used to calculate assay quality parameters S/B, S/N and Z’ are presented in section 
2.1.3. Inter-plate and inter-day variation values were calculated using the normalised mid-signal 
values (samples treated with 6,000 IU/ml polymyxin B) of three plates and two separate days.  
 
To study standard compounds in the assays, two alternative exposure times of 1.5 h and 24 h were 
chosen. However, the LDH leakage assay was observed to suffer from a compromised signal 
window during the 24-h exposure probably due to spontaneous LDH leakage. Therefore, the assay 
was used to determine the total LDH amount as an indicator of cell number with this longer 
exposure time. Testing for the dose-dependent increase in LDH leakage after 1.5 h of exposure 
resulted in only a minor effect of gramicidin S and polymyxin B (30% - 40% of the maximal 
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activity in the collected assay media at the highest concentration used). No LDH activity detectable 
over the reagent background was measured from media samples exposed to 5-fluorouracil or 
camptothecin. Only exposure to Triton X-100 yielded a sigmoidal dose-response relationship that 
reached the maximal LDH activity determined by lysis control samples giving an IC50 value of 
0.05% (v/v). The two other assays based on WST-1 tetrazolium salt reduction and determination of 
the cellular ATP level were able to detect decreases in cell viability after 1.5 h of exposure to all 
five compounds, and IC50 values were determined from the dose-response experiments. A 
statistically significant difference in the IC50 values for camptothecin and Triton X-100 was 
observed between the two assays with the ATP assay being more sensitive in both cases 
(camptothecin IC50 values 21.0 ± 2.1 µM in the WST-1 assay and 6.8 ± 1.5 µM in the ATP assay 
and Triton X-100 IC50 values of 0.02 ± 0.0008% in the WST-1 assay and 0.005 ± 0.002% in the 
ATP assay). No statistical difference in IC50 values was observed between the WST-1 and ATP 
assay for gramicidin S, polymyxin B and 5-fluorouracil. 
 
The ATP assay was used to evaluate the effects of standard compounds on cell lines of different 
origins. In addition to the Caco-2 cells used for assay validation, the human bronchial epithelium 
Calu-3 and human hepatocellular Huh-7 cell lines were used as well as the baby hamster kidney 
BHK21 cells that were used for antiviral studies. The IC50 values determined after 24 h of exposure 
are presented in Figure 2 in I. A statistically significant difference in IC50 values between the cell 
lines was found for camptothecin and 5-fluorouracil using one-way ANOVA whereas gramicidin S 
and polymyxin B had similar potencies in all cell lines. Pair-wise comparison of the camptothecin 
and 5-fluorouracil values identified the Huh-7 line as demonstrating differential values whereas no 
statistically significant differences were seen between Caco-2, Calu-3 and BHK21.   
 
The 24-h exposure time was chosen for antiviral counter-screens based on the results of this study. 
In addition to the BHK21 cell line used for antiviral assays, Huh-7 cells were selected for hit 
compound profiling with either 24-h or 48-h exposure times. 
 
5.2. Antiviral assay development 
5.2.1. Infection time scale and RNA labelling assay (II) 
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The replication rate of wild-type SFV was studied by RNA synthesis rate experiments in which 
incorporation of [3H]uridine into newly synthesised viral genomes was monitored using sequential 
1-h labelling pulses to establish a relevant time scale for antiviral assay endpoints. Graphs of the 
[3H]uridine incorporation rates from experiments with different multiplicities of infection are 
shown in Figure 4. As indicated by the graphs, each decrease by one order of magnitude in 
infection multiplicity shifts the time of maximal RNA synthesis onward by two hours (also see 
Table 1 in II). Independent of the MOI used, the same plateau level is finally reached to indicate 
the maximal RNA synthesis rate. To allow for a setup in which several infection cycles are 
included, a MOI of 0.001 was selected for the antiviral assay. A detection time point of 14 h was 
set for all future experiments based on the RNA labelling data as it represented the time at which 
the RNA synthesis rate is reaching it maximum. 
 
Figure 4. RNA synthesis rate of SFV in BHK21 cell cultures infected with different multiplicities. 
The time (in hours) given on the X-axis represents the time of culture lysis at the end of each 
[3H]uridine pulse.  A. MOI = 10; B. MOI = 1; C. MOI = 0.01; D. MOI = 0.001. 
 
5.2.2. Luciferase-based screening assay using Semliki Forest virus (II)  
 
A reporter gene-based screening assay was developed to use the surrogate virus approach in the 
identification of alphavirus inhibitors. To this end, an infectious clone of SFV was used in which 
the Rluc insertion was made into the nonstructural protein-coding region of the SFV genome 
between the sequences encoding nonstructural proteins 3 and 4. An additional protease cleavage 
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site was added to allow proteolytic processing by the viral nsP2 protease (Figure 5a). A SFV-Rluc 
virus stock was propagated by in vitro transcription and subsequent RNA electroporation into 
BHK21 cells; and the primary stock collected from electroporated cultures was further used to 
propagate the P2 working stock. The working stock of SFV-Rluc had a titer of 1.5 x 109 PFU/ml, 
which is comparable to the wild-type SFV stocks obtained by similar means (e.g. the wt SFV stock 
used in these studies has a titer of 4.5 x 109 PFU/ml). Proper processing of the viral polyprotein 
P1234 was confirmed by western blot analysis of lysates from infected cell culture samples using 
anti-nsP3 antiserum, which resulted in the identification of a protein band of the correct size and 
increasing intensity during the course of infection.  
 
 
Figure 5. A. Genomic organisation of SFV and SFV-Rluc; B. Rluc activity of BHK21 culture 
lysates infected with an MOI of 0.001 SFV-Rluc.  
 
Under visual inspection by light microscopy, SFV-Rluc had a cytotoxic phenotype at 20 h 
postinfection (MOI = 0.01), which was indistinguishable from the wt phenotype under these same 
conditions. [3H]uridine incorporation experiments were also conducted with SFV-Rluc in which the 
virus reached similar maximal uridine incorporation rates as the wt SFV. No delay was observed in 
reaching the plateau. Rluc activity was also analysed in samples collected at sequential time points 
from cultures infected with SFV-Rluc at an MOI of 0.001, and it was found to stay linear over the 
time scale used (Figure 5b). 
 
5.2.3. Chikungunya virus replicon assay (IV)  
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To screen for inhibitors of CHIKV, a screening system was built using a BHK21-based replicon 
cell line that persistently expresses CHIKV replicase proteins. The CHIKV sequence originated 
from a viral strain isolated in La Réunion during the 2005-2006 outbreak and was modified with 
adaptive mutations in the nsP2 region. The structural protein-coding region was replaced with the 
enhanced green fluorescent protein (EGFP) gene fused with the puromycin acetyltransferase 
sequence and the Renilla luciferase gene was fused to the C-terminus of nsP3. The selected cell line 
was designated BHK-CHIKV-NCT; it was grown under puromycin selection and showed stable 
marker gene expression at least for 20 passages. 
 
 
Figure 6. Expression of EGFP and Rluc marker genes of the BHK-CHIKV-NCT replicon cell line 
with different media and cell seeding densities. A. EGFP expression after 24 h of incubation; B. 
EGFP expression after 48 h of incubation; C. Rluc expression after 24 h of incubation; D. Rluc 
expression after 48 h of incubation. All cultures were seeded in complete medium and incubated 
overnight before the onset of the described experiment. 
 
To establish the antiviral assay, the replicon cells were seeded in 96-well plates and grown in either 
complete BHK medium, DMEM supplemented with 5% FBS or MEM + 0.2% BSA, and either in 
the presence or absence of 5 µg/ml puromycin. Different seeding densities of the cells were used to 
study the expression of replicon marker genes under different assay conditions. As indicated by the 
graphs presented in Figure 6, the replicon cell line demonstrates high EGFP and Rluc signals in 
both growing (cell seeding densities of 7,500 and 15,000 cells/well) and confluent (seeding density 
of 30,000 cells/well) cell cultures. Cell cultures grown in MEM + 0.2% BSA show less intense 
signals due to the slower replication rate of the cells while the difference between the growing 
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cultures in DMEM supplemented with 5% FBS and those grown in complete medium is small. The 
presence of puromycin had no effect on EGFP or Rluc expression after 24 or 48 h of incubation 
(data not shown), and therefore, all inhibitor studies were carried out without puromycin. 
 
In preliminary assays with standard compounds, ribavirin and mycophenolic acid reduced ATP 
levels of the replicon cell line by 40% to 55% when growing cell cultures were exposed to 50 µM 
concentrations of the compounds. Similar 48-h exposures of the confluent cell cultures did not lead 
to a decrease in the cellular ATP levels. Because the confluent cultures were shown to maintain 
high levels of EGFP and Rluc expression, they were chosen as the primary alternative for antiviral 
assays. Studies using the nucleoside analogue 3’-amino-3’-deoxyadenosine (Table 7) indicated that 
a 48-h exposure is sufficient for the suppression of replicon expression with an antiviral agent. 
DMEM supplemented with 5% FBS was selected for the assay medium instead of complete BHK 
medium or MEM + 0.2% BSA to prevent culture overgrowth or the induction of apoptotic 
pathways during the experiments. 
 
Table 7. Suppression of CHIKV replicon marker genes by 3’-amino-3’deoxyadenosine 
 
Marker 
 
Medium 
24 h 
7,500 
cells/well 
24 h 
30,000 
cells/well 
48 h 
7,500 
cells/well 
48 h 
30,000 
cells/well 
EGFP full medium 64.4 68.0 36.9 33.2 
EGFP DMEM + 5% FBS 63.2 68.7 35.3 38.6 
Rluc full medium 67.1 58.8 23.4 16.7 
Rluc DMEM + 5% FBS 63.9 60.3 21.7 16.4 
Values represent the mean of the remaining EGFP and Rluc expression as a percentage compared 
to the untreated controls. All experiments were performed in triplicate. 
 
 
5.3. Antiviral assay validation  
5.3.1. Assay performance (II and IV)  
 
Antiviral assays were optimised to be run in a 96-well plate format and were evaluated for their 
robustness and reproducibility based on signal windows and signal variation. Assay quality 
parameters from optimised assay protocols for the SFV-Rluc and CHIKV replicon assays are 
presented in Table 8. The same parameters from the colorimetric CPE reduction assay used in 
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follow-up studies in IV are included for comparison. The threshold value of 0.5 set for optimal 
robustness was met with the SFV-Rluc assay and CHIKV replicon assay as indicated by the Z’ 
values. The CPE assay resulted in a Z’ value 0.44, which was lower than that of the three other 
assays but still close to the 0.5 limit. 
 
Table 8. Assay quality parameters of the miniaturised antiviral assays. 
Assay S/B S/N Z’ Inter-plate 
variation 
Inter-day 
variation 
SFV-Rluc 152.3 6.4 0.52 8.9 11.6 
SFV CPE  4.3   5.8 0.44 12.2 8.5 
CHIKV replicon, EGFP 65.3 16.3 0.79 4.7 7.4 
CHIKV replicon, Rluc 231.4 30.7 0.74 6.2 6.9 
Formulas used to calculate the assay quality parameters S/B, S/N and Z’ are presented in section 
2.1.3. Inter-plate and inter-day variation values were calculated using the mean signal value of the 
normalised mid-signal (samples treated with 100 µM ribavirin in the SFV-Rluc assay and 15 µM 
ribavirin in the CPE reduction assays and replicon assay) of three plates and two separate days. 
 
5.3.2. Standard compounds (II and  IV)  
 
As part of the assay validation process, four chemical agents including ribavirin, mycophenolic 
acid, 6-azauridine and chloroquine were studied in the developed assays. All four compounds have 
previously documented activity against alphaviruses (Briolant et al., 2004; Helenius et al., 1982; 
Huffman et al., 1973). The antiviral IC50 values of these compounds in different assays are 
collected in Table 9. RNA labelling studies were not included in the comparison as this assay 
requires the use of actinomycin D to block host cell RNA synthesis. Actinomycin D neutralises the 
antiviral activity of ribavirin via uncharacterised cellular interactions, which makes the use of this 
combination irrelevant (Malinoski and Stollae, 1980). Chloroquine did not show inhibition of 
CHIKV replicon marker gene expression, and thus, no IC50 value was obtained in this assay. This 
result is consistent with chloroquine’s known mode of action, which is based on the inhibition of 
virus entry and maturation (Savarino et al., 2003). 
 
Ribavirin and mycophenolic acid exhibited statistically significantly higher IC50 values in the SFV-
Rluc assay as compared to CPE reduction, whereas chloroquine demonstrated similar potency in 
the two assays. On the other hand, 6-azauridine was found to have only a minor inhibitory potential 
against SFV in both assays (30% – 40% inhibition at the highest concentration used) but was much 
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more potent in the CHIKV replicon assay. Ribavirin and mycophenolic acid were also assayed for 
alphavirus inhibition in the presence of external guanosine supplementation. Both compounds 
showed no inhibition of SFV-Rluc at the highest concentration used (300 µM) when the culture 
medium was supplemented with 50 µg/ml guanosine. Guanosine supplementation prevented the 
inhibition by ribavirin treatment in both the EGFP and Rluc readings in the CHIKV replicon assay. 
Inhibition of the replicon marker genes by mycophenolic acid was also reversed by guanosine 
supplementation, yet the highest mycophenolic acid concentration (200 µM) still resulted in 35% 
inhibition of the EGFP readout. As discussed in section 2.3.1., no direct evidence on the 
mechanism of action of alphavirus inhibition is available for ribavirin or mycophenolic acid. 
However, in light of this evidence, the inhibition of IMPDH is the most prominent player in this 
respect. 
 
Table 9. The 50% inhibitory concentrations of ribavirin, mycophenolic acid, 6-azauridine and 
chloroquine in the antiviral assays used.  
Compound SFV Rluc IC50 (µM) 
SFV CPE 
IC50 (µM) 
SINV CPE  
IC50 (µM) 
CHIKV 
EGFP  IC50 
(µM) 
CHIKV 
Rluc IC50 
(µM) 
Ribavirin 95.1 28.1 51.8 8.8 25.4 
Mycophenolic acid 121.3 39.0 44.4 -1.5 4.1 
Chloroquine 13.4 8.2 11.3 - - 
6-azauridine >200 >200 >200 2.4 3.1 
The values represent the means from two individual experiments performed in triplicate. 
 
A recent review introduced the antimalarial drug quinine as a potential candidate for alphavirus 
antiviral therapy (Gould et al., 2009). Based on unpublished results, quinine was stated to have an 
IC50 value of 0.1 µg/ml (0.3 µM) against CHIKV infection in Vero cells. The authors also indicated 
that CHIKV strains grown in increasing quinine concentrations accumulate mutations in nsP1 
indicating that virus capping is a potential target for antiviral therapy. Despite this observation, 
quinine showed no effect on reporter gene expression in the CHIKV replicon. Quinine did have an 
IC50 value of 71 µM in the full virus assay using SFV-Rluc (data not included in original 
publications).  
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5.4. Screening for alphavirus inhibitors 
5.4.1. Nucleoside analogues (II) 
 
Nucleoside analogues have classically been at the centre of antiviral screening as several screening 
campaigns have been aimed at the identification of structural modifications in the nucleoside 
skeleton that would lead to selective affinity for viral polymerases or other enzymes responsible for 
viral DNA or RNA metabolism.  
 
In II, a collection of 29 nucleoside analogues was assayed against SFV and SIN in the RNA 
labelling assay and also studied in the reporter gene-based assay using SFV-Rluc. These studies 
revealed two structural modifications that exert an inhibitory potential against the two viruses: 
substitutions on C3 of the sugar residue and the introduction of large substituents on N6 of the 
purine base. The secondary assay of the study (plaque reduction assay) demonstrated that 
compound 15 (3’-amino-3’deoxyadenosine) was the most efficient among the studied analogues 
and reduced the SFV yield by 820-fold at a concentration of 100 µM. 3’-amino-3’-deoxyadenosine 
showed moderate effect on BHK21 cell viability in II and was found to have a cell viability IC50 
value of 187.1 µM in Huh-7 cells as measured by ATP assay after 48 h of exposure (Table 1 in IV). 
A selectivity index in the range of 10 was thus achieved for this nucleoside. 
 
The nucleoside analogues were also assayed against the BHK-CHIKV-NCT cell line for their 
ability to suppress expression of the CHIKV replicon (data not presented in the original 
publications). Figure 7 presents the results from these experiments in which the replicon cell line 
was exposed to 50 µM nucleoside analogues for 48 h. The results obtained in these experiments 
indicate similar inhibitory activities for each nucleoside as reported against SFV in II, derivatives 
12, 15 and 16 showing the most intense inhibition.   
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Figure 7. Effects of the nucleoside analogues on expression of the EGFP and Rluc reporter genes 
of the CHIKV replicon in the BHK-CHIKV-NCT cell line. Columns represent the mean and SD 
values of three replicates. See Figure 1 in II for the chemical structures of each nucleoside 
analogue. 
 
5.4.2. Semisynthetic betulin-derived compounds (III) 
 
The pentacyclic triterpenoid betulin is an abundant natural product that represents up to one-third 
of the dry weight of the outer bark of white birches (Betula sp.). The oxidised form of betulin, 
betulinic acid, can also be found in birch bark in minor quantities and is present in various 
unrelated plant species. Betulinic acid and its derivatives are widely studied for their proapoptotic 
and immunomodulatory properties, and accumulating evidence has also demonstrated their 
antimicrobial activities (Alakurtti et al., 2004; Cichewicz and Kouzi, 2004). 
 
The third publication of the current study covers the screening of antialphaviral activity of 51 
semisynthetic derivatives of betulin and betulinic acid bearing modification of both the C3 and C28 
hydroxyl groups and the 20,29 double bond. The activity distribution of the derivatives based on 
the antiviral and cytotoxic properties is visualised in the scatter plot in Figure 8.  
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Of the 51 derivatives tested in the primary assay, 19 scored below the hit limit (<20% SFV 
replication remaining) and met the set criterion for cell viability (>80%). These derivatives were 
subjected to dose-response experiments and extended cell viability evaluation. 3,28-O-
diacetylbetulin (compound 4 in III) had the lowest IC50 value among these derivatives (9.1 µM; 
Table 2 in III), but betulonic acid 11 and betulinic acid 13 also had IC50 values in the same range 
(13.3 µM and 14.6 µM, respectively; no statistically significant difference between the three 
compounds). For further cell viability testing, Huh-7 cells were exposed to 500 µM concentrations 
prior to determination of the ATP level. With few exceptions, the hit compounds showed no 
decrease in ATP levels at this concentration. Thus, selectivity indices were not calculated as in the 
absence of true cell viability IC50 values this measurement would not rank the compounds by 
selectivity but rather would offer just another measure of compound potency.  
 
Figure 8. Scatter plot of the antiviral and cytotoxic properties of the betulin-derived compounds. 
Each point represents one assayed compound; the location of the point is defined by its impact on 
SFV-Rluc replication and Huh-7 cell viability at 50 µM. 
 
Three betulin-derived compounds (betulinic acid, 38-O-tetrahydropyranylbetulin and the 
cycloadduct of 4-phenyl-1, 2, 4-triazolidine-3, 5-dione and 3β, 28-di-O-acetylbetulin-12, 18-diene; 
whose chemical structures are presented in Figure 9; correspond to compounds 13, 17 and 41 in 
III) were also analysed in administration time experiments using a high multiplicity SFV-Rluc 
infection (10 PFU/cell). The betulin derivatives as well as 3’-amino-3’-deoxyadenosine were 
subjected to either delayed administration (1 h or 2 h postinfection) or early withdrawal (1 h 
postinfection) under conditions where expression of the Rluc reporter gene is measured after giving 
time for only a single cascade of virus replicative machinery (detection at 4 h postinfection). Under 
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such conditions, betulinic acid and 3’-amino-3’-deoxyadenosine decreased Rluc activity when 
administered 1 h or 2 h postinfection but had no effect on luciferase activity in samples where the 
compounds were washed away at 1 h (Figure 3 in III). 28-O-tetrahydropyranylbetulin and the 
heterocyclic betulin derivative 41 differed from betulinic acid and 3’-amino-3’-deoxyadenosine in 
the assay as they did not suppress Rluc marker gene expression in any of the administration times 
used for the experiments indicating that the target site of these two derivatives is not likely to 
involve virus entry or replication. As the experiment time scale covers only a single infectious 
cycle and the marker gene is produced as a part of the replicase polyprotein, maturation inhibitors 
do not show suppression of Rluc in this setup. 
, 
 
Figure 9. Chemical structures of betulinic acid, 38-O-tetrahydropyranylbetulin and the cycloadduct 
of 4-phenyl-1, 2, 4-triazolidine-3, 5-dione and 3β, 28-di-O-acetylbetulin-12, 18-diene  
 
Table 10. IC50 values of betulinic acid, 28-O-tetrahydropyranylbetulin and the heterocyclic betulin 
derivative 41 against SFV, SINV and CHIKV;. 
Compound SFV  IC50 (µM) 
SINV  
IC50 (µM) 
CHIKV  EGFP 
IC50 (µM) 
CHIKV Rluc 
IC50 (µM) 
Betulinic acid 14.6 0.5 1.5 4.0 
28-O-tetrahydropyranylbetulin 17.2 1.9 - - 
Cycloadduct of 4-phenyl-1,2,4-
triazolidine-3,5-dione and 3β,28-
di-O-acetylbetulin-12,18-diene 
19-7 6.4 - - 
Values represent the data from two individual experiments performed in triplicate. - , no inhibition 
observed 
 
The same three betulin derivatives were also tested in the CHIKV replicon system (data not 
included in the original publications). Consistent with data from the administration time 
experiments, 28-O-tetrahydropyranylbetulin and the heterocyclic betulin derivative 41 did not 
inhibit expression of the replicon reporter genes while betulinic acid suppressed EGFP and Rluc 
expression with IC50 values of 1.5 µM and 4.0 µM, respectively (Table 10). In III, the three 
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compounds were also demonstrated to inhibit SINV replication with IC50 values in the low 
micromolar range (experiments conducted with the RNA labelling assay). 
  
Furthermore, synergism studies were carried out between the three betulin-derived compounds and 
3’-amino-3’-deoxyadenosine using the Loewe synergism model. Dose-response curves of each 
betulin derivative were determined in the presence of varying nucleoside concentrations. I values 
for the combinations that were calculable (excluding those leading to a response in either the upper 
or lower plateau of the dose-response curve) are presented in Table 11. As indicated by the values, 
the observed synergism was concentration-dependent and most intense at low compound 
concentrations.  
 
Table 11. Interaction indices for betulinic acid (13), 28-O-tetrahydropyranylbetulin (17) and the 
heterocyclic betulin derivative  41 in combination with 3’-amino-3’-deoxyadenosine.  
   
D1 (µM) D2 (µM) I (13) I (17) I (41) 
10 0.5 0.96 0.27 0.26 
50 0.5 1.12 0.51 - 
2 2 - 0.90 1.50 
10 2 1.27 0.48 0.25 
50 2 1.56 0.54 - 
0.08 5 0.28 - - 
0.4 5 0.25 1.44 0.27 
2 5 0.35 0.24 0.18 
10 5 0.52 0.81 - 
0.08 20 0.51 0.91 0.82 
0.4 20 0.88 - 0.53 
2 20 0.99 - - 
0.08 50 1.23 1.28 0.92 
D1 represents the concentration of each betulin derivative and D2 is the concentration of 3’-amino-
3’-deoxyadenosine. 
 
 
5.4.3. Library of natural products (IV)  
 
In IV, a library of 124 natural compounds was screened for inhibition of alphavirus replication 
using the SFV-Rluc assay for the primary screen. The natural product collection consisted mainly 
of flavonoids, coumarins, gallates and other phenolic compounds, most of which are well-
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characterised plant secondary metabolites. Such metabolites have undergone evolutionary selection 
to serve a role in the defence and interaction paths used by plants; and natural compounds are thus 
regarded as a rich source for bioactive structures (Koehn and Carter, 2005). 
 
A complete list of screening compounds and primary screening results is presented in 
Supplementary information for IV. The activity distribution of the natural compounds in the 
primary screen using the SFV-Rluc assay is shown in Figure 10A and contains a high proportion of 
anti-SFV compounds. A confirmatory assay was conducted for all compounds yielding less than 
25% remaining SFV replication in the primary screen along with a counter-screen for BHK21 cell 
viability (ATP assay, 24-h exposure). Fifteen compounds (Table 1 in IV) were defined as screening 
hits (hit rate = 12.1%) after this filtering. Furthermore, a number of compounds in the library 
showed moderate SFV-Rluc inhibition (points between the 25% and 50% lines in Figure 10A).  
 
Confirmed hits of the study were subjected to dose-response experiments of which representative 
results are presented in Figure 10B. Results from the SFV-Rluc screening assay were compared 
using the ATP cell viability assay involving Huh-7 cells exposed for 48 h, and compounds yielding 
selectivity indices higher than 10 were selected for further analyses. 
 
Figure 10. A. Primary screen of natural compounds using the SFV-Rluc assay. Results represent 
the remaining SFV replication in each sample treated with a compound concentration of 50 µM; n 
= 124. B. Representative examples of dose-response curves of confirmed hits of the NC screen. 
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A secondary assay on the SFV-induced cytopathic effect was next utilised for the selected hit 
compounds using BHK21 cell viability quantification by the WST-1 reduction assay. Similar 
experiments were also carried out using the CPE assay. Further follow-up studies were performed 
with SFV yield assays where the viral titers were determined from infected cultures treated with 
compound concentrations of 50 µM. CPE reduction and virus yield assays confirmed the anti-SFV 
activity of most of the screening hits, and no statistically significant difference in IC50 values was 
found between SFV and SINV for CPE reduction (Table 2 in IV) All of the compounds that 
reduced the SFV- and SINV-induced CPE reduced also SFV titers 10 – 100 fold in the virus yield 
assay. 
The natural compounds were also assayed in the BHK-CHIKV-NCT replicon cell line where the 
flavonoids apigenin, chrysin, naringenin and silybin suppressed the levels of both the EGFP and 
Rluc markers. The coumarins bergapten and coumarin 30 did not reduce the marker levels. Potency 
evaluation in dose-response experiments resulted in IC50 values of 22.5 µM and 28.3 µM for 
apigenin and 25.8 µM and 30.0 µm for naringenin (EGFP and Rluc readings, respectively), while 
chrysin and silybin had IC50 values ranging from 45.8 µM to 71.1 µM (Table 3 in IV). Chemical 
structures of the four flavonoids are presented in Figure 11, which reveals that all of the compounds 
have a 5,7-dihydroxyflavone structure.  
 
Figure 11. Chemical structures of apigenin (A), chrysin (B), naringenin (C) and silybin (D).  
 
Also screening artefacts arisen by autofluorescent screening compounds were dencountered in the 
NC screen. Figure 12 shows the fluorometric and luminometric readings of an experiment 
measuring the effect of coumarin 30 on the CHIKV replicon markers. The fluorescence reading of 
the assay samples containing 50 µM coumarin 30 (leftmost columns) yielded a signal that was 
approximately five-fold greater than the untreated replicon samples (columns in the middle) while 
the luminometric readout gave a signal that was in the same range as the untreated control. The 
rightmost columns represent the fluorescent and luminescent signals of 50 µM coumarin 30 alone 
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(diluted in the assay buffer) confirming that the observed bias in the readings was a consequence of 
the compound’s autofluorescence 
.  
Figure 12. Fluorescent and luminescent readings from experiments with coumarin 30 on the 
CHIKV replicon.  
5.4.4. Library of pharmaceutical compounds (IV)  
  
An alternative approach to find novel inhibitors of alphavirus replication was applied in IV by 
evaluating a library of drug molecules in a screening assay against SFV-Rluc. Finding a chemical 
agent already approved for clinical use would allow for rapid proceeding to the efficacy evaluation 
in animal models and possibly in human volunteers as the long-term safety profile of clinically 
used drugs has already been characterised and approved by authorities for at least some indications. 
The identification of an inhibitory effect by a molecule with a known pharmacological target may 
also provide clues for elucidating the pathways and signalling cascades involved in the viral 
replication process within the cells. Even though the indication for which the drug is approved may 
not represent the only target site of the compound, it provides a good starting point for studies on 
the observed inhibitory effects. 
 
The library of pharmaceutical compounds tested in Publication IV consisted of 234 bioactive 
synthetic compounds, most of which are drugs that are or have previously been in clinical use. The 
compounds represent several therapeutic areas including drugs for cardiovascular and metabolic 
diseases, antidepressants, antipsychotics and other psychiatric drugs, antibiotics and analgesics. 
 
A similar screen design as described above for the natural compounds was used in the primary 
screen, the confirmatory assays and the cell viability counter-screen of compounds in the 
pharmaceutical collection. After the exclusion of compounds yielding non-reproducible results and 
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those that decreased BHK21 cell viability, 12 compounds were defined as screening hits (hit rate = 
5.0%). Furthermore, 24 compounds in the library showed moderate SFV-Rluc inhibition (points 
between the 25% and 50% lines in Figure 13A).  Figure 13A represents the activity distribution of 
the pharmaceutical compounds at a concentration of 50 µM in the primary screen against SFV-
Rluc; and representative examples of dose-response curves are shown in Figure 13B. Using the 
same procedure as with the natural compounds, the follow-up studies on SFV- and SINV-induced 
CPE reduction and the SFV yield assay confirmed the inhibition of two distant members of the 
alphavirus genus by the hit compounds (Table 2 in IV).  
 
Figure 13. A. Primary screen of pharmaceutical compounds in the SFV-Rluc assay. Results 
represent the remaining SFV replication in each sample treated with a compound concentration of 
50 µM; n = 234. B. Representative examples of dose-response curves of confirmed hits among the 
PC compounds. 
 
The PC screen hit list included the antipsychotic drugs chlorpromazine, perphenazine, 
thiethylperazine and thioridazine as well as a first-generation antihistaminic agent methdilazine and 
the antiparkinsonism agent ethopropazine (also known as profenamine). Despite their slightly 
different indications reflecting the differential affinities for the related plasma membrane receptor 
proteins, all six of these compounds share the same 10H-phenothiazine core structure consisting of 
three fused rings of which the middle one contains nitrogen and sulphur atoms in para positions. 
Ethopropazine and thioridazine were also shown to reduce SFV- and SIN-induced CPE by the IC50 
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values of 17.1 µM and 21.4 µM (ethopropazine) and 19.3 µM and 37.3 µM (thioridazine), 
respectively. Both compounds also showed moderate inhibition of the SFV yield when they were 
present during the infection at a concentration of 50 µM. None of the six compounds inhibited the 
CHIKV replicon as measured by expression of the two marker genes, which implies that the target 
site for the antiviral activity of these compounds lies outside the viral replication phase. 
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6. DISCUSSION 
6.1. Use of cell viability assays   
 
Cell viability assays were originally developed some decades ago mainly for immunological and 
oncological purposes and were later adapted for bioactivity assay counter-screens and for 
predictive toxicology. Despite the correlation of cytotoxicity assays with in vivo data (see section 
2.4.1.), quantitative and even qualitative differences in cytotoxicity assay results between different 
assay endpoints are not hard to find (Larksome et al., 2007; Mueller et al., 2004; Puttonen et al., 
2008). The assay endpoint plays a crucial role in assay sensitivity and governs the exposure time 
required as indicated by the results of I in the current study. The results also indicate that the nature 
of the test samples should be taken into account in assay selection, which is also emphasised by the 
experimental artefacts described for transporter proteins and cellular redox state. To allow more 
reliable conclusions, parallel use of more than one assay endpoint has been suggested (Wilson, 
2000). Calculation of selectivity indices in antiviral screening relies on the determination of cell 
viability IC50 values from the selected assay. Therefore, the quantitative precision and reliability of 
the cell viability assays are as essential as optimisation of the antiviral assays themselves. In the 
current study, reproducibility of the cell viability data is confirmed by the use of statistical 
parameters to monitor data homogeneity throughout the screens. 
 
In general, improved sensitivity has been considered a beneficial factor in assay selection. 
However, definitive answers on optimal sensitivity regarding both predictive toxicology and 
bioassay counter-screening are yet to be found. According to data presented in this study, the ATP 
assay is the most sensitive of the tested assays for detecting chemical-induced cellular stress, and 
similar results have been reported elsewhere (Mueller et al., 2004), When optimised for minimal 
signal deviation, this assay is capable of reliably detecting 10% to 20% changes in cellular ATP 
pools. However, it is not clear whether a mild or moderate decrease in intracellular ATP levels 
would result in any harmful in vivo effects, or whether it affects viral replication enough to classify 
the antiviral result as a false positive. The well-documented examples of resveratrol, curcumin and 
other phytochemicals with a biphasic dose-response relationship in cell viability illustrate this 
question. The adaptive stress response induced by low doses of these phytochemicals triggers 
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changes leading to cytoprotection whereas the decrease in cell metabolism induced by higher 
concentrations may lead to cell death (Mattson, 2007). 
 
6.2. Antiviral assay development   
 
CPE reduction has been established as the standard endpoint for antiviral screening due to its wide 
applicability in panels of unrelated viruses. The classical form of the CPE reduction assay involves 
visual inspection of cell cultures under a microscope to evaluate the extent of the cytopathic 
effectand it is thus labour-oriented, subjective and only semiquantitative in nature. These technical 
obstacles can be overcome by using a suitable cell viability assay method, such as a tetrazolium 
salt. However, the problem of distinguishing between the cytopathy caused by virus and the test 
compound-borne toxicity remains unsolved. Even though chemical agents affecting the host cell 
viability were not relevant as lead candidates the dissection into inactive and toxic derivatives 
would be required for accurate SAR studies. Furthermore, the general endpoint of the assay 
provides few options for follow-up studies to determine the target site of the antiviral activity. 
 
In II, a novel luminescent assay was described for screening for inhibitors of alphavirus replication. 
One of the key features of luminometric detection is the high dynamic range of the signal, which is 
beneficial in antiviral screening where linear detection over several orders of magnitude is required. 
This feature was highlighted by the S/B value achieved with the assay (approximately 150 as 
compared to 4.3 in the colorimetric CPE reduction assay). The signal shows some deviation 
presumably due to the relative error in the small original inoculum (100 PFU/well) but the wide 
signal window compensates for the noise and the achieved Z’ value of 0.5 indicates assay 
robustness. Furthermore, signal deviation does not interfere with assay precision as the normalised 
mean signal determined as the response of cultures treated with 100 µM ribavirin show only 
approximately 10% deviation (8.9% between plates and 11.6% between days).   
 
The developed assay utilises a strain of the Semliki Forest virus encoding for the Renilla luciferase 
marker, which is inserted within the nonstructural protein-coding region of the viral genome. Thus, 
the expression of Rluc reflects the production of viral replicase proteins allowing for the monitoring 
of this essential aspect of viral replication. The luciferase is inserted with an extra protease 
cleavage site recognised by viral nsP2 protease, which leads to release of the marker protein into 
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the cytoplasm of infected cells during the course of P1234 polyprotein processing. This feature was 
confirmed by the correct size of the nsP3 protein as determined by immunoblotting of the lysates of 
infected cell cultures. The release of the reporter is probably an important contributor to the genetic 
stability of SFV-Rluc; the genome of alphaviruses is extremely condensed (a total of approximately 
11,500 – 11,800 base pairs) and any nonessential components that cause delays or not being 
essential in replication are likely to be rapidly lost when the virus is passaged in cell culture. 
However, SFV-Rluc exhibits over 90% luciferase positivity in a third passage of low multiplicity 
infections, each of which consists of two to three virus replication cycles. 
 
Use of the luciferase marker virus also allows for follow-up assays in which the infection 
multiplicity and timescale can be changed to determine the antiviral activities targeting certain 
steps of the viral replication cycle. By comparing data from low and high multiplicity infections, 
inhibitors of virus maturation can be identified as agents showing antiviral activity in a low 
multiplicity infection, but not showing suppression of the marker gene levels at 4 - 5 h in a high 
multiplicity infection (as done in III). On the other hand, the low detection limit of luciferase in 
high multiplicity infections yields a detectable signal as soon as 30 minutes after inoculum 
administration. The capped positive-stranded RNA genome of SFV is readily transcribed as soon as 
it is released from the nucleocapsid into the cytoplasm to yield the initial fraction of nonstructural 
proteins. Assaying the effect of antiviral hits on such early stage events in the viral replication cycle 
may provide indicative data on the target site of the antiviral action, but no definitive conclusions 
can be drawn to distinguish between the entry and replication inhibition. Replication in wt viral 
infection is initiated as soon as the first P1234 precursors are formed and thus takes place 
simultaneously with further translation of the initial RNA strand.  In this respect, more solid 
mechanistic information could be achieved by using a system in which replication is restricted, 
such as a high multiplicity infection of a replication-negative TS mutant virus strain at an elevated 
temperature. In general, when comparing data from infections with different multiplicities, one 
should be bear in mind that the antiviral potency of many chemical agents is dependent on infection 
multiplicity and sufficiently high compound concentrations should be used to avoid false 
interpretations. 
 
The luminometric antiviral assay based on SFV-Rluc was validated using the known alphavirus 
inhibitors ribavirin, mycophenolic acid, chloroquine and 6-azauridine. Ribavirin and mycophenolic 
acid showed higher IC50 values in the reporter assay than in the CPE reduction assay used for 
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comparison. Chloroquine, 6-azauridine and the screening hits identified in studies II, III and IV 
did not show significant differences in IC50 values between the two assays. Both ribavirin and 
mycophenolic acid are inhibitors of inositol monophosphate dehydrogenase (IMPDH), but it is not 
clear if the observed differences in sensitivity between the two assays are related to this mode of 
action.  
 
Another new antiviral assay was described in IV in the form of a stable cell line expressing CHIKV 
replicase proteins and two marker genes. The noncytopathic, persistent phenotype of the replicon 
was achieved by combining a point mutation and a 5 aa insertion into the CHIKV nsP2 sequence. 
Renilla luciferase was placed in the end of nsP3, but with no additional protease cleavage site. 
EGFP was fused with puromycin acetyltransferase and placed under a subgenomic promoter to 
maintain replication by selection pressure. Huge dynamic ranges and excellent Z’ values were 
achieved for both the luminometric and fluorometric readings after optimisation steps. 
Reproducibility was also demonstrated by only approximately 5% deviations in the normalised 
mid-signals (cultures treated with 15 µM ribavirin). 
 
Alphaviruses replicate efficiently in cells that are in the resting state and do not require cell 
division. Confluent cell cultures were also selected for antiviral assays with the BHK-CHIKV-NCT 
replicon cell lines as the cells were shown to maintain marker gene levels in the medium even in 
the absence of puromycin at least for 48 h. Furthermore, confluent cell cultures were less sensitive 
to test compound-borne decreases in cellular ATP levels. Although compounds causing slower cell 
replication rates at high concentrations may not be relevant as future lead compounds, the 
compromised cell culture viability at higher compound concentrations limits the determination of 
reliable dose-response curves. 
 
The intracellular dynamics of noncytotoxic alphaviruses and their replicons have been shown to be 
essentially different from their wild-type counterparts; minus strand synthesis is continuous and 
replication complexes are unstable and undergo recycling in the persistent viral infection (Sawicki 
et al., 2003). The causality relationship between the two aspects is not obvious. It is unknown 
whether instability of the replication complexes allows for the formation of new replication 
complexes and production of the minus strand RNA by these new replication complexes or whether 
the failure of viral and host cell factors to stop minus strand synthesis is the factor that destabilises 
the replication complexes. Notably, despite the continuous minus strand synthesis no accumulation 
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of total RNA has been seen in the persistent infections. In general, noncytotoxic SFV and SIN 
replicons produce low levels of RNA rather than cause its accumulation (Sawicki et al., 2006).  
 
Whatever the causal relationship of these two aspects, the continuous minus strand synthesis in the 
replicon system allows for the identification of screening hits affecting this step of alphavirus 
replication and is thus considered a benefit for the screening system. The recycling of replication 
complexes also gives rise to two alternatives concerning the screening hit activities; the compounds 
can act by inhibiting the production of new replication complexes or by inhibiting the function of 
established RCs.  
 
In general, the noncytopathic phenotype of alphaviruses is linked to mutated forms of nsP2 but host 
cell factors also play a role in regulating the viral replication process in this respect. Mouse embryo 
fibroblasts (MEF) deficient in RNase L, but not thise lacking in protein kinase R or MX-1, exhibit a 
similar phenotype as noncytotoxic nsP2 mutant viruses (Sawicki et al., 2003). Even though the 
persistent infection caused by nsP2 mutant viruses and wild-type viruses in RNase L-deficient cell 
lines have similar phenotypes it has not been elucidated if the two aspects are interconnected and 
whether they are the only players in the virus-cell interactions responsible for the noncytotoxic 
phenotype. A simple assay setup to identify the undescribed components in this interplay could be 
offered by the combination of the primary HTS screen for agents (siRNA or small organic 
molecules) that reduce wild-type virus CPE with a counter-screen of the hits for viral replication 
using the reporter gene assay described in II. The identification of siRNA or chemical probes 
causing a noncytotoxic yet replicative viral phenotype would give us new tools for better 
understanding of this process. 
 
6.3. Aspects of alphavirus antiviral lead discovery  
 
The proinflammatory cytokines IL-1, IL-6 and TNF-α play a central role in the onset of clinical 
symptoms of the febrile illness caused by CHIKV, RRV and other arthritogenic alphaviruses (Kam 
et al., 2009, Rulli et al., 2005). High circulating levels of these cytokines during the acute viremia 
have been suggested to predict disease severity, and the role of proinflammatory cytokines has 
shown to be central in the development of joint and muscle manifestations (Lidbury et al., 2008; 
Ng et al., 2008). The relative emphasis on the relationship between viral replication and the 
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cytokine response is an essential point to consider in the chemotherapy used to treat infected 
individuals. Even though high viral titers in the bloodstream correlate to some extent with a severe 
clinical picture, there are currently no data to demonstrate that suppression of viral titers in the 
blood or acceleration of virus clearance would lead to clinical benefits after the onset of the 
cytokine storm. However, effective suppression of viral loads by antiviral agents may still be useful 
for prophylactic medication or for prevention of virus transmission. Evaluation of the role of virus 
clearance in clinical treatment would require the use of chemical agents that solely target the virus 
and leave the immune system unmodified, but none of the agents currently in common use are 
suitable for this task. However, the design and development of inhibitors targeting viral enzymes 
could provide tools for such studies. In contrast to many other viral species, the nsP4 RNA 
polymerase may not be the optimal starting point as a screening target given the technical obstacles 
in assaying this enzymatic activity. The papain-like protease in the C-terminal portion of nsP2 
could provide an option; however, the selectivity of potential inhibitors should be considered. On 
the other hand, targeting the unique capping function of nsP1 could lead to specific inhibition. 
Additionally, competitive binding of ADP-ribose in the nsP3 macrodomain should be validated as 
an antiviral target. 
 
The combination of antiviral and immunomodulatory effects is also likely to be the main factor 
causing different outcomes in in vitro and in vivo studies of antiviral agents. The small molecule 
alphavirus inhibitors ribavirin and mycophenolic acid exert their activities via the depletion of 
cellular GTP pools, which at least in the case of mycophenolic acid, leads to suppression of 
immune system cells. Mycophenolic acid is clinically approved for immunosuppressive use while 
most in vivo studies on its antiviral activity have been left unpublished due to unsatisfactory results 
(Diamond, 2009). Ribavirin has also been shown to possess immunomodulatory properties and to 
modulate the balance between helper T cell populations among its other effects (Hollgren et al., 
1998). Ribavirin is used to treat chronic HCV infections in combination with IFN-α; in this 
combination IFN has been suggested to act as the antiviral agent and ribavirin as the 
immunomodulatory agent (De Ckercq et al., 2009; Feld and Hoofmagle, 2005). Chloroquine also 
has well-documented immunomodulatory effects that involve both inhibition of TNF-α production 
and impairment of TNF-α-induced signalling in its target cells (Jeong et al., 1997; Jeong et al., 
2002). The role of unfavourable immunomodulatory effects has been suggested in the failure of the 
2007 clinical trial against CHIKV; and an earlier study, chloroquine enhanced SFV replication in 
mice and was interpreted in the same context (De Lamballerie et al., 2008; Maheshwari et al., 
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1991). However, the results are still be regarded as inconclusive due to the small number of 
patients enrolled into the clinical trial (n = 27 in both the active and control groups) as well as the 
differences in biology between the animal models. 
 
The use of the animal models to study the antialphaviral effects of any chemical agent should be 
carefully considered. Classically, the standard animal model used in alphavirus studies has been the 
age-dependent encephalitis of neonatal infected mice using prolonged survival or protection from 
death as the endpoint. More recently, adult mice have been infected with CHIKV or RRV to induce 
an arthritogenic disease better reflecting the pathology seen in human infection with these viruses. 
Thus far, no published reports on the characterisation of antiviral agents in these models are 
available. The neurotrophic potential of Old World alphaviruses in neonatal mice is considered a 
consequence of their immature immune system as most of these viruses are apathogenic in adult 
mice with a mature interferon response (Muller et al., 1994; Ryman et al., 2000). When 
administering a drug candidate with immunomodulatory properties, it is not obvious that the 
infection outcome will be similar in the different models. The proper interpretation of the results is 
crucial for making the right decisions on the continuation or withdrawal of any drug candidate. 
  
CHIKV and other alphaviruses are sensitive to IFN treatment in vitro (Briolant et al., 2004; 
Sourisseau et al., 2007) and treatment with pegylated IFN-α has also been shown to protect mice 
against VEEV-induced encephalitis (Lukaszewski et al., 2000). However, no attempt to treat 
alphavirus infection by commercially available interferon preparates has been published. The 
underlying reasons presumably include not only the unsuitability of injection therapy in most 
alphavirus endemic areas but also the uncertainty of the potential risks concerning the worsening of 
acute symptoms in response to the treatment.  
 
More experimental information on the immunopathogenesis of the arthritogenic infectious disease 
is required to guide antialphaviral drug discovery in the right direction. Given the well-established 
role of TNF-α in inflammatory responses and the recent evidence of its role in the arthritic 
symptoms of CHIKV infections, clinically approved biotechnological drugs targeting this cytokine 
could be used as an experimental treatment for treating severe alphavirus infections. Monoclonal 
anti-TNF-α antibodies and soluble chimeric TNF-α receptors have been proven efficacious in many 
autoimmune diseases including rheumatoid arthritis. The experimental use of these preparations 
alone or in combination with a suitable antiviral drug, administered either during the acute viremia 
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or after its clearance in the arthritogenic mouse model would shed more light on the relevance of 
immunomodulation in the therapy. 
 
6.4. Chemical scaffolds for alphavirus inhibitors  
 
The core structure of 10H-phenothiazine was identified in 6 of the 12 pharmaceutical compounds 
scored as screening hits against SFV in study IV. In a recent HTS campaign against Western 
equine encephalitis virus, Peng et al. (2009) described thieno[3,2,b]bipyrrole as a lead structure for 
antialphaviral therapy. As indicated by the chemical structures presented in Figure 14, both the 
structure identified by Peng et al. and the 10H-phenothiazine structure are heterocycles containing 
nitrogen and sulphur atoms in their ring structures. 
 
However, the two structures differ from each others in several key aspects: i. 10H-phenothiazines 
consist of three fused rings whereas in thieno[3,2,b]bipyrroles the third ring is separated from the 
two other rings by a carbonyl group; ii. thieno[3,2,b]bipyrrole consist of five-atom rings whereas in 
10H-phenothiazines all rings are six-member; iii. 10H-phenothiazines contain nitrogen and sulphur 
atoms in the same ring whereas thieno[3,2,b]bipyrroles contain heteroatoms in different rings. The 
 
Figure 14. A. 10H-phenothiazine structure found in six of the screening hits in IV; B. core 
structure of thieno[3,2,b]bipyrrole derivatives identified as chemical leads against WEEV as 
reported by Peng et al., 2009. 
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thienyl pyrroles were identified as alphavirus inhibitors in a replicon-based screen and have been 
shown in another study to inhibit hepatitis C virus RdRp (Ontoria et al., 2006). On the other hand, 
none of the six pharmaceutical compounds sharing the 10H-phenothiazine structure suppressed 
expression of the CHIKV replicon in IV indicating either a significant difference in sensitivity 
between SFV and CHIKV or, more likely, the exertion of compound activity via a target site not 
present in the replicon system. Therefore, the  differences in chemical structures between the two 
lead structures are presumably tied to different modes of antiviral activity. 
 
Four of the compounds sharing the 10H-phenothiazinyl group were antipsychotic and two act on 
histamine and cholinergic receptors. It is worth noting that all six agents target CNS diseases 
indicating that these drugs are able to cross the blood-brain barrier to reach their target site. This 
feature is highly beneficial in the treatment of alphavirus infections especially as New World 
neurotrophic alphaviruses use CNS neurons as host cells in infected individuals leading to 
encephalitis. Recent CHIKV epidemics have been characterised by an increasing number of 
neurological symptoms; the ability of CHIKV to infect neurons is currently a matter of debate 
(Courfier et al., 2008; Das et al., 2010; Sourisseau et al., 2007). However, presence of the virus in 
the CNS is made obvious by virus isolates collected from the cerebrospinal fluid of infected 
individuals. The main route of CNS penetration is thought to be the choroid plexus as the blood-
brain barrier remains intact in infected mice. 
 
6.5. Natural products as alphavirus inhibitors  
 
The limited number of natural products among the published inhibitors of alphaviral replication is 
likely due to lack of studies in this area rather than the failure to identify such compounds. The 
recent study of seco-pregnane glaucogenin C and its glycosides (Li et al., 2007) demonstrated that 
natural products are an important unexplored source of alphavirus inhibitors. The use of natural 
products as a starting material for bioactivity screening is also considered to offer the best chance 
to identify compounds with previously indescribed mechanisms of action (Newman and Cragg, 
2007). This idea is true for glaucogenin C and its glycosides; they were shown to specifically 
suppress alphavirus subgenomic RNA synthesis via a yet to be described molecular interaction.  
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An ethnopharmacological approach for the identification of alphavirus inhibitors was taken in an 
Australian study on medicinal plants used by aboriginals and revealed the activity of extracts from 
two local plant species (Eremophila latrobei and Pittosporum phylliraeoides) against Ross-River 
virus  (Semple et al., 1998). The extracts were found to show no antiviral activity against poliovirus 
or human cytomegalovirus indicating at least some degree of selectivity for RRV. The maximal 
antiviral effect observed was approximately 40% inhibition of RRV-induced CPE, but the 
concentration and the identity of the active ingredients in the extracts were not studied. However, 
the authors pointed out that the extracts have been reported to contain sesquiterpenoids and 
triterpenoids, which bear structural similarity to the betulin-derived compounds demonstrated in 
this work to be alphavirus inhibitors. 
  
Betulinic acid and its esters are widely distributed in the plant kingdom and have also been reported 
to be present in various unrelated medicinal plants on different continents (Aponte et al., 2008; 
Nick et al., 1995; Zuo et al., 2008). Many of these areas are also sites of past CHIKV outbreaks, 
and the majority of these regions still rely on traditional herbal remedies either as their only source 
of medication or to supplement Western medicine. Given the shortage in alphavirus antivirals and 
the unlikelihood of the appearance of new licensed chemical entities in this respect, the rational use 
of locally available plant- or marine-derived preparations should be promoted by investigating the 
antiviral activities of these secondary metabolites and their combinations. 
 
In addition to the betulin-derived compounds, the natural products studied in the current work 
included flavonoids and other polyphenolic compounds. Flavonoids have been extensively studied 
in anti-HIV drug discovery as HIV-I integrase inhibitors, reverse transcriptase inhibitors and for 
their ability to downregulate the expression of chemokine receptors required for HIV entry (Asres 
et al., 2005). Various flavonoids are also known to inhibit RNA viruses from the rhinovirus and 
picornavirus families. These studies have focused on virus entry as the antiviral target indicating 
that flavonoids may target the viral capsid proteins to prevent the uncoating process (Jassim and 
Naji, 2003). Studies presented in this work (IV) identified several flavonoids as inhibitors of 
alphavirus replication with apigenin being the most consistent inhibitor in the assays used. 
Apigenin and three other 5,7-dihydroxyflavones (chrysin, naringenin and silybin) also showed 
inhibition in the CHIKV replicon cell line indicating that they exert activities related to the viral 
replication phase rather than entry or maturation.  
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Data from other sources are available concerning the immunomodulatory activities of both the 
flavonoids and betulin-derived compounds described as alphavirus inhibitors in the current study. 
Flavonoids are widely studied in vitro and in vivo for their anti-inflammatory activities, which 
include the direct antioxidative effect via free radical scavenging but also more specific activities 
such as inhibition of the proinflammatory enzymes involved in eicosanoid biosynthesis 
(phospholipase A2, cyclooxygenase 1 and lipoxygenase), downregulation of leukocyte adhesion 
molecules in endothelial cells and inhibition of the production and/or secretion of proinflammatory 
cytokines (Garcia-Lafnente et al., 2009). Hydroxyflavones such as luteolin and apigenin have been 
reported to efficiently inhibit TNF-α-stimulated IL-6 production as well as IL-1-induced 
prostaglandin production in human endothelial cells. Luteolin and the isoflavone genistein are also 
potent inhibitors of IL-1α, IL-6 and TNF-α production in LPS-stimulated macrophages (Gerritsen 
et al., 1995; Xagorari et al., 2001). 
 
Betulin and betulinic acid like many other triterpenoids play a dual role in modulating the functions 
of the immune system. Betulinic acid has been shown to stimulate interferon secretion in LPS-
induced macrophages but has also been shown to inhibit phospholipase A2 and reduce nitric oxide 
production in stimulated leucocytes (Honda et al., 2006; Tseng and Liu, 2004; Yun et al., 2003). In 
vivo data on the immunomodulatory effects of pure betulinic acid are not available. However, the 
seed extract of an Indian fluid Ziziphus mauritiana in which one of the major constituents is 
betulinic acid was recently demonstrated to induce interferon production and promote the Th1 
lymphocyte-mediated immune response in mice (Mishap et al., 2010).  As discussed in previous 
sections, the optimal combination of antiviral and immunomodulatory activities in the treatment of 
alphaviral diseases remains to be found. In vivo studies on these and other chemical agents would 
provide evidence to support taking further steps towards the relevant therapy. 
 
6.6. Concluding remarks and future prospects 
 
Success in the early phases of drug discovery is governed by an interplay of understanding the 
target biology, the choice of screening material and the ability to build biologically relevant and 
robust assay systems for screening campaigns. The rational drug discovery process is based on the 
selection of validated target molecules for chemical intervention in the given condition and the 
small molecule ligand indentified in screening campaigns is expected to prove its efficacy in a 
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suitable in vivo model within the limits of its kinetic properties. Accumulating structural 
information on the target proteins has allowed the use of virtual screening and in silico ligand 
design tools to promote the shift from diverse to more focused screening libraries and has allowed 
for educated guesses in the design and identification of more specific and more potent ligands. 
Whether the chemical leads identified in these processes truly  represent more specific modulators 
of biological targets or an artificial specificity due to the lack of long-term studies remains to be 
seen. While specific, high-affinity ligands certainly contribute to target validation, the ultimate 
question concerning medical treatment is whether a specific inhibitor of a single target provides the 
best medical advantage given the complex nature of physiological systems rich in homeostatic and 
pleiotropic mechanisms. Examining older drugs reveals that it is the rule rather than exception that 
these agents have moderate but wider affinity profiles or even several distinct modes of action. 
Though the lack of specificity may obviously manifest itself as a risk for adverse drug effects, the 
superior in vivo antiviral activity of ribavirin as compared to a more potent IMPDH inhibitor 
mycophenolic acid for example implies that the different target sites essentially contribute to the 
final clinical benefits achieved by the medical treatment.  
 
In addition to questions related to the search for selectivity and specificity, the field of bioactivity 
screening is facing the challenge of less-validated targets and interest in targeting biological 
processes of a poorly characterised nature. Rather than being a step in a linear process from target 
selection to lead discovery, bioactivity screening is contributing more and more to the identification 
and validation of target proteins. In this respect, phenotypic assays are the intuitive screening 
strategy and more consideration must be given to the selection of screening libraries that confer 
blind screening to the approaches allowing rapid follow-up studies. 
 
The recently increased interest in alphaviruses and the antiviral therapies targeting them is still 
waiting to be turned into advances in the clinical treatment of the diseases caused by these 
pathogens. Studies with classical chemical inhibitors, such as chloroquine and ribavirin, indicate 
that more detailed understanding of the virus-host cell interactions and the role of 
immunomodulation in antialphaviral chemotherapy is required for rational design and screening of 
potential antiviral compounds. While more complex high-content screening systems and in vitro 
models using tools such as co-cultures of different cell populations are yet to be built, the antiviral 
assays described in the current study provide robust tools for the screening of alphavirus inhibitors. 
Combined with pathway biology, assays for specific target molecules, virtual screening and other 
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tools these assays will hopefully guide us closer to effective strategies for fighting Chikungunya 
and other alphaviral pathogens. 
 
The rapid mutation rate of RNA viruses is likely to lead in the emergence in still new pathogens 
and epidemic outbreaks in future. While investigation of the molecular details of RNA virus 
replication is essential for providing validated drug targets, this process may not provide the rapid 
response required to fight emerging pathogens. Therefore, access to efficient phenotypic screening 
strategies using robust assay formats is the first line of defence when combined with careful 
selection of the screening material. The chance for off-label use of readily licensed medicines is a 
choice for serious consideration yet rhis strategy requires the frequently cited serendipity. In the 
long run, the combination of phenotypic assays with diverse natural product collections may prove 
invaluable in the identification of the elegant starting points for future target-based lead discovery 
campaigns. 
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